Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

ERK

" in MCE Product Catalog:

By Targets:	ERK (150) 5-HT Receptor (4) Acyltransferase (2) Adrenergic Receptor (2) Akt (21) AMPK (2) Amyloid-β (2) Apoptosis (74) Arginase (1) Arrestin (1) Aryl Hydrocarbon Receptor (3) Autophagy (20) Bacterial (2) Bcr-Abl (1) Beta-secretase (2) Bradykinin Receptor (2) Btk (2) c-Kit (3) c-Met/HGFR (5) Calcium Channel (2) Cannabinoid Receptor (3) Casein Kinase (2) Caspase (11) CCR (3) CDK (6) Cholecystokinin Receptor (1) Cholinesterase (ChE) (3) COX (6) CXCR (2) Cytochrome P450 (1) Dipeptidyl Peptidase (1) DYRK (1) EGFR (17) Endogenous Metabolite (18) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (1) FAK (2) Farnesyl Transferase (1) Ferroptosis (2) FGFR (1) FLT3 (4) Fungal (1) GPR35 (1) GPR55 (4) GSK-3 (5) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (2) Histone Methyltransferase (1) HSP (2) HSV (1) iGluR (1) IKK (1) Insulin Receptor (2) Integrin (3) Interleukin Related (6) Isotope-Labeled Compounds (2) Itk (1) JAK (3) JNK (12) Keap1-Nrf2 (3) LPL Receptor (1) Macrophage migration inhibitory factor (MIF) (2) MAPKAPK2 (MK2) (2) MEK (22) Melanocortin Receptor (4) Melatonin Receptor (1) mGluR (3) MicroRNA (1) MMP (6) MNK (1) NF-κB (24) p38 MAPK (16) PAI-1 (1) PAK (1) Parasite (3) PARP (1) PDGFR (5) PERK (6) PGE synthase (1) Phosphatase (6) Phosphodiesterase (PDE) (2) Phospholipase (2) PI3K (6) Pim (1) PKA (1) PKC (3) Potassium Channel (5) PPAR (2) Prostaglandin Receptor (3) PROTACs (2) Raf (5) Ras (22) Reactive Oxygen Species (12) RET (1) Ribosomal S6 Kinase (RSK) (1) ROCK (2) ROS Kinase (3) SARS-CoV (2) SHP2 (1) Sirtuin (1) Sodium Channel (7) SphK (4) Src (2) STAT (5) Survivin (1) Syk (4) TAM Receptor (2) TGF-beta/Smad (1) TNF Receptor (7) Toll-like Receptor (TLR) (3) Topoisomerase (1) Trk Receptor (3) TrxR (1) Tyrosinase (2) VEGFR (8) Wnt (6) β-catenin (6)
By Research Areas:	Cancer (225) Cardiovascular Disease (35) Endocrinology (3) Infection (10) Inflammation/Immunology (82) Metabolic Disease (25) Neurological Disease (44)

By Targets:

ERK (150)

5-HT Receptor (4)

Acyltransferase (2)

Adrenergic Receptor (2)

Akt (21)

AMPK (2)

Amyloid-β (2)

Apoptosis (74)

Arginase (1)

Arrestin (1)

Aryl Hydrocarbon Receptor (3)

Autophagy (20)

Bacterial (2)

Bcr-Abl (1)

Beta-secretase (2)

Bradykinin Receptor (2)

Btk (2)

c-Kit (3)

c-Met/HGFR (5)

Calcium Channel (2)

Cannabinoid Receptor (3)

Casein Kinase (2)

Caspase (11)

CCR (3)

CDK (6)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (3)

COX (6)

CXCR (2)

Cytochrome P450 (1)

Dipeptidyl Peptidase (1)

DYRK (1)

EGFR (17)

Endogenous Metabolite (18)

Epigenetic Reader Domain (2)

Estrogen Receptor/ERR (1)

FAK (2)

Farnesyl Transferase (1)

Ferroptosis (2)

FGFR (1)

FLT3 (4)

Fungal (1)

GPR35 (1)

GPR55 (4)

GSK-3 (5)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (2)

Histone Methyltransferase (1)

HSP (2)

HSV (1)

iGluR (1)

IKK (1)

Insulin Receptor (2)

Integrin (3)

Interleukin Related (6)

Isotope-Labeled Compounds (2)

Itk (1)

JAK (3)

JNK (12)

Keap1-Nrf2 (3)

LPL Receptor (1)

Macrophage migration inhibitory factor (MIF) (2)

MAPKAPK2 (MK2) (2)

MEK (22)

Melanocortin Receptor (4)

Melatonin Receptor (1)

mGluR (3)

MicroRNA (1)

MMP (6)

MNK (1)

NF-κB (24)

p38 MAPK (16)

PAI-1 (1)

PAK (1)

Parasite (3)

PARP (1)

PDGFR (5)

PERK (6)

PGE synthase (1)

Phosphatase (6)

Phosphodiesterase (PDE) (2)

Phospholipase (2)

PI3K (6)

Pim (1)

PKA (1)

PKC (3)

Potassium Channel (5)

PPAR (2)

Prostaglandin Receptor (3)

PROTACs (2)

Raf (5)

Ras (22)

Reactive Oxygen Species (12)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

ROCK (2)

ROS Kinase (3)

SARS-CoV (2)

SHP2 (1)

Sirtuin (1)

Sodium Channel (7)

SphK (4)

Src (2)

STAT (5)

Survivin (1)

Syk (4)

TAM Receptor (2)

TGF-beta/Smad (1)

TNF Receptor (7)

Toll-like Receptor (TLR) (3)

Topoisomerase (1)

Trk Receptor (3)

TrxR (1)

Tyrosinase (2)

VEGFR (8)

Wnt (6)

β-catenin (6)

By Research Areas:

Cancer (225)

Cardiovascular Disease (35)

Endocrinology (3)

Infection (10)

Inflammation/Immunology (82)

Metabolic Disease (25)

Neurological Disease (44)

332

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: ERK

Cat. No.	Product Name	Target	Research Areas

HY-136579

ASN007 ERK-IN-3	ERK	Cancer
ASN007 (ERK-IN-3) is a potent and orally active inhibitor of *ERK. ASN007 inhibits ERK1/2* with low single-digit nM IC₅₀ values. ASN007 can be used for the research of cancers driven by RAS mutations.

HY-136579A

ASN007 benzenesulfonate ERK-IN-3 benzenesulfonate	ERK	Cancer
ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of *ERK. ASN007 benzenesulfonate inhibits ERK1/2* with low single-digit nM IC₅₀ values. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations.

HY-151934

ERK-IN-6	Apoptosis	Cancer
ERK-IN-6 (compound 6g) is an potent anti-proliferation agent against esophageal squamous cell carcinoma (ESCC). ERK-IN-6 induces cell apoptosis via *ERK* pathway. ERK-IN-6 can be used for the research of ESCC.

HY-142437

ERK1/2 inhibitor 8
ERK Cancer

ERK1/2 inhibitor 8 is a potent ERK inhibitor with an IC₅₀ of 0.48 nM for ERK2 (WO2021110168A1, WX007).
HY-142433

ERK1/2 inhibitor 7
ERK Cancer

ERK1/2 inhibitor 7 is a potent ERK inhibitor with an IC₅₀ of 0.94 nM for ERK2 (WO2021110168A1, WX006).

ERK1/2 inhibitor 8	ERK	Cancer
ERK1/2 inhibitor 8 is a potent *ERK* inhibitor with an IC₅₀ of 0.48 nM for ERK2 (WO2021110168A1, WX007).

ERK1/2 inhibitor 7	ERK	Cancer
ERK1/2 inhibitor 7 is a potent *ERK* inhibitor with an IC₅₀ of 0.94 nM for ERK2 (WO2021110168A1, WX006).

HY-113592

ERK-IN-4	ERK	Cancer
ERK-IN-4 is an *ERK* inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2.

HY-153350

ERK-IN-7
ERK Cancer

ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively.

ERK-IN-7	ERK	Cancer
ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent *ERK* inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively.

HY-150606

ERK5-IN-4	ERK	Cancer
ERK5-IN-4 (compound 34b) is a potent and selective inhibitor of extracellular signal-related kinase 5 (ERK5). ERK5-IN-4 inhibits *ERK5* (full-length) and truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with an IC₅₀ of 77 nM and 300 nM, respectively.

HY-128341

ERK5-IN-2	ERK	Cancer Cardiovascular Disease
ERK5-IN-2 is an orally active, sub-micromolar, selective *ERK5* inhibitor with IC₅₀s of 0.82 μM, 3 μM for *ERK5* and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis.

HY-14403

ERK5-IN-1
ERK Cancer

ERK5-IN-1 is a potent ERK5 inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC₅₀ of 26 nM.

ERK5-IN-1	ERK	Cancer
ERK5-IN-1 is a potent *ERK5* inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC₅₀ of 26 nM.

HY-150605

ERK5-IN-3	ERK	Cancer
ERK5-IN-3 (compound 33j) is a potent and selective *ERK5* (extracellular signal-related kinase 5) inhibitor, with an IC₅₀ of 6 nM. ERK5-IN-3 shows antiproliferation activity against Hela cells, with an IC₅₀ of 31 nM.

HY-133084

ERK-IN-2
ERK Cancer

ERK-IN-2 is a ERK2 inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 might lead to off-target toxicity and/or off-target activity at dose >10 μM.
HY-112300

ERK2 IN-1
ERK Cancer

ERK2 IN-1 is a selective ERK2 inhibitor with an IC₅₀ of 7 nM.

ERK-IN-2	ERK	Cancer
ERK-IN-2 is a *ERK2* inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 might lead to off-target toxicity and/or off-target activity at dose >10 μM.

ERK2 IN-1	ERK	Cancer
ERK2 IN-1 is a selective *ERK2* inhibitor with an IC₅₀ of 7 nM.

HY-112287

ERK1/2 inhibitor 1	ERK	Cancer
ERK1/2 inhibitor 1 is a potent, orally bioavailable *ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC₅₀* of 3.0 nM against ERK1 and ERK2, respectively.

HY-112469

ERK Inhibitor II (Negative control)	ERK Insulin Receptor	Metabolic Disease
ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes.

HY-145025

ERK1/2 inhibitor 3	ERK	Cancer Inflammation/Immunology
ERK1/2 inhibitor 3 is a potent inhibitor of *ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK*1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1).

HY-145026

ERK1/2 inhibitor 4	ERK	Cancer Inflammation/Immunology
ERK1/2 inhibitor 5 is a potent inhibitor of *ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK*1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1).

HY-145027

ERK1/2 inhibitor 5	ERK	Cancer
ERK1/2 inhibitor 5 is a potent inhibitor of *ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK*1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1).

HY-145028

ERK1/2 inhibitor 6	ERK	Cancer Inflammation/Immunology
ERK1/2 inhibitor 6 is a potent inhibitor of *ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK*1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1).

HY-133084A

ERK-IN-2 free base	ERK	Cancer
ERK-IN-2 free base is a *ERK2* inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 free base might lead to off-target toxicity and/or off-target activity at dose >10 μM.

HY-135906

*CK2/ERK8-IN-1*	Casein Kinase ERK Pim DYRK Apoptosis	Cancer
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (K_i of 0.25 µM) and *ERK8* (MAPK15, ERK7) inhibitor with IC₅₀s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with K_is of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy.

HY-P3751

[Tyr8] Bradykinin	Bradykinin Receptor ERK	Endocrinology Cardiovascular Disease
[Tyr8] Bradykinin is a B₂ kinin receptor agonist. [Tyr8] Bradykinin also stimulates ERK1/2 phosphorylation. [Tyr8] Bradykinin can be used as an internal standard.

HY-142066

4′-Demethylnobiletin	PKA ERK iGluR	Neurological Disease
4′-Demethylnobiletin is a bioactive metabolite that activates the *PKA/ERK/CREB* signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment associated with NMDA receptor antagonism by stimulating ERK signaling.

HY-114491A

Rineterkib hydrochloride	ERK Raf	Cancer
Rineterkib hydrochloride (compound B) is an orally available *ERK1* and *ERK2* inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.

HY-114491

Rineterkib	ERK Raf	Cancer
Rineterkib (compound B) is an orally available *ERK1* and *ERK2* inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF. Storage: protect from light.

HY-N6076

Tenuifoliside A	ERK	Neurological Disease
Tenuifoliside A is isolated from Polygala tenuifolia, has anti-apoptotic and antidepressant-like effects. Tenuifoliside A exhibits its neneurotrophic effects and promotes cell proliferation through the *ERK/CREB/BDNF* signal pathway in C6 cells.

HY-150687

ZINC12409120	ERK	Metabolic Disease
ZINC12409120 is a high selective *ERK* inhibitor. ZINC12409120 acts on disrupting FGF23:α-Klotho interaction to inhibit ERK activity with an IC₅₀ of 5.0 μM.

HY-107620

PD 198306	MEK	Neurological Disease
PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.

HY-124097

HNMPA-(AM)3	Insulin Receptor	Metabolic Disease
HNMPA-(AM)3 is a cell-permeable and selective insulin receptor tyrosine kinase inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis.

HY-153011

ROCK-IN-5	ROCK ERK GSK-3	Neurological Disease Cardiovascular Disease
ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, *ERK, GSK, and AGC* protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research.

HY-N3711

Dehydrocrenatine	JNK ERK Apoptosis	Neurological Disease
Dehydrocrenatidine, a β-carboline alkaloid that can be isolated from Picrasma quassioides. Dehydrocrenatidine induces cell apoptosis by activates *ERK* and JNK. Dehydrocrenatidine inhibits invasion and migration of cancer cells, it also suppresses neuronal excitability to exert analgesic effects.

HY-146319

MIF-IN-6	Macrophage migration inhibitory factor (MIF)	Cancer Metabolic Disease Inflammation/Immunology
MIF-IN-6 (compound 2d) is a potent macrophage migration inhibitory factor (MIF) inhibitor with an IC₅₀ of 1.4 μM and a K_i value of 0.96 μM, respectively. MIF-IN-6 attenuates MIF-induced ERK phosphorylation and inhibits proliferation of A549 cells.

HY-114436

MRTX-1257	Ras	Cancer
MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.

HY-119039

RU-301	TAM Receptor	Cancer Inflammation/Immunology
RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates *ERK* activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis.

HY-N8211

Gypenoside L	p38 MAPK ERK NF-κB	Cancer Inflammation/Immunology
Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines. Gypenoside L also can activate p38 and ERK MAPK pathways and NF-κB pathway to induce senescence. Gypenoside L exhibits anti-tumor and anti-inflammatory activities.

HY-134000

Emodic acid NSC624610	p38 MAPK NF-κB ERK JNK VEGFR MMP	Cancer
Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, *ERK* and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP, thereby inhibiting the invasion and migration potential of cancer cells.

HY-148510

HKB99	Phosphatase	Cancer
HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 inhibits the formation of invasive pseudopodia and increases the level of PAI-2 in vitro. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC).

HY-P4497

Prolylserine	ERK Others	Cancer
Prolylserine, a dipeptide, is an inhibitor of melanogenesis production in Mel-Ab cells. Prolylserine decreases expression of microphthalmia-associated transcription factor (MITF) and tyrosinase, induces phorphosylation of *ERK, but not cAMP response element binding protein (CREB)*.

HY-N1381

Periplocin	Apoptosis	Cancer Inflammation/Immunology
Periplocin is a cardiotonic steroid isolated from root-bark Periploca sepium Bunge. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase.

HY-114436S

MRTX-1257-d6 MRTX-1257-d₆	Isotope-Labeled Compounds	Cancer
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.

HY-100609

4-P-PDOT	Melatonin Receptor	Neurological Disease
4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity).

HY-113756A

Latanoprost acid	Prostaglandin Receptor	Inflammation/Immunology
Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes.

HY-N0590

Corynoxeine	ERK	Cardiovascular Disease
Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent *ERK1/ERK2* inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.

HY-15947

Ravoxertinib
GDC-0994
ERK Cancer

Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC₅₀ of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

Ravoxertinib GDC-0994	ERK	Cancer
Ravoxertinib (GDC-0994) is an orally active *ERK* kinase inhibitor with an IC₅₀ of 6.1 nM and 3.1 nM for *ERK1* and *ERK2*, respectively.

HY-15947A

Ravoxertinib hydrochloride GDC-0994 hydrochloride	ERK	Cancer
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for *ERK* kinase activity with IC₅₀ of 6.1 nM and 3.1 nM for *ERK1* and *ERK2*, respectively.

HY-16558

Butein 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60^c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).

HY-120200

YF-452	VEGFR	Cancer Cardiovascular Disease
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research.

HY-N8418

Cearoin
Autophagy Reactive Oxygen Species ERK Apoptosis Cancer

Cearoin increases autophagy and apoptosis through the production of ROS and the activation of ERK.
HY-15665

XMD17-109
ERK Cancer

XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC₅₀ of 162 nM.

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC).

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research.

HY-N1374

Magnolin	ERK	Inflammation/Immunology
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of *ERK1* and *ERK2* with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-P1844

Chemerin-9 (149-157)	Akt ERK Reactive Oxygen Species Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism.

HY-15816A

Ulixertinib hydrochloride BVD-523 hydrochloride; VRT752271 hydrochloride	ERK	Cancer
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of *ERK1/2* kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

HY-116807

Dihydrolipoic Acid DHLA	Reactive Oxygen Species	Inflammation/Immunology Neurological Disease
Dihydrolipoic Acid (DHLA) is an excellent antioxidant capable of scavenging almost any oxygen-centered radical. Dihydrolipoic acid exhibits anti-inflammatory properties in various diseases. Dihydrolipoic Acid exerts a preventive effect via ERK/Nrf2/HO-1/ROS/NLRP3 pathway in LPS-induced sickness behavior rats. Dihydrolipoic Acid can be used for the reaserch of depression.

HY-112181

KO-947
ERK Cancer

KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors.

HY-N2283

Deltonin	ERK Akt Endogenous Metabolite	Cancer
Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis, with antitumor activity; Deltonin inhibits *ERK1/2* and AKT activation.

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active *ERK1/2* inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer.

HY-18932

DEL-22379	ERK Apoptosis	Cancer
DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a K_d estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC₅₀ of ~0.5 μM.

HY-B0513

Methylthiouracil MTU	NF-κB TNF Receptor Interleukin Related ERK	Inflammation/Immunology Cancer
Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and *ERK1/2*.

HY-15816

Ulixertinib BVD-523; VRT752271	ERK	Cancer
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of *ERK1/2* kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

HY-123938

Risovalisib CYH33	PI3K	Cancer
Risovalisib (CYH33) is an orally active, highly selective PI3Kα inhibitor with IC₅₀s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. Risovalisib inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. Risovalisib has potent activity against solid tumors.

HY-N2312

Mogrol
ERK STAT Cancer

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.
HY-126288

ASTX029
ERK Cancer

ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor. ASTX029 has anti-cancer activity.

HY-12275

FR 180204	ERK Apoptosis	Cancer
FR 180204 is an ATP-competitive and selective *ERK* inhibitor. FR 180204 inhibits *ERK1* and *ERK2* with IC₅₀s of 0.51 μM (K_i=0.31 μM) and 0.33 μM (K_i=0.14 μM), respectively.

HY-50846

SCH772984	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive *ERK* inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naïve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations.

HY-108886

JWG-071	ERK	Cancer
JWG-071 is the first reported kinase-selective chemical probe for *ERK5. JWG-071 improves ERK5 activity and BRD4 selectivity. JWG-071 will be a much-needed chemical probe for deconvoluting ERK*5 and BRD4 pharmacology.

HY-123938A

CYH33 methanesulfonate	PI3K	Cancer
CYH33 methanesulfonate is an orally active, highly selective PI3Kα inhibitor with IC₅₀s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. CYH33 methanesulfonate inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 methanesulfonate has potent activity against solid tumors.

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and *ERK1/ERK2*, respectively.

HY-16642A

LY2828360	Cannabinoid Receptor	Neurological Disease
LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB₂) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.

HY-N1507

Tracheloside	Estrogen Receptor/ERR	Cancer
Tracheloside is an antiestrogenic lignin. Tracheloside promotes keratinocyte proliferation through ERK1/2 stimulation. Tracheloside is a good candidate to promote wound healing.

HY-119272

EF24	ERK Caspase	Cancer
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.

HY-15312

WP1066
STAT JAK Apoptosis Cancer

WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.

HY-122246

ML192	GPR55 PKC ERK Arrestin	Metabolic Disease
ML192 is a selective ligand antagonist of GPR55. ML192 inhibits the β-arrestin trafficking, *ERK1/2* phosphorylation and PKCβII translocation.

HY-124740

ML00253764	Melanocortin Receptor	Cancer
ML00253764 is a selective melanocortin receptor 4 (MC4R) antagonist, can induce apoptosis by inhibiting ERK1/2 and Akt phosphorylation, and has anticancer activity.

HY-W001174

2,5-Dihydroxyacetophenone	ERK NF-κB	Inflammation/Immunology
2,5-Dihydroxyacetophenone, isolated from Rehmannia glutinosa, inhibits the production of inflammatory mediators in activated macrophages by blocking the *ERK1/2* and NF-κB signaling pathways.

HY-50706

Selumetinib AZD6244; ARRY-142886	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-50706A

Selumetinib sulfate AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-108330

AG126 Tyrphostin AG126	ERK	Inflammation/Immunology
AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of *ERK1* and *ERK2* at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research.

HY-19696B

Tauroursodeoxycholate dihydrate Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	ERK Caspase Apoptosis Endogenous Metabolite	Cancer
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits *ERK*.

HY-111407

MK-8353 SCH900353	ERK	Cancer
MK-8353 (SCH900353) is a potent, selective and orally available *ERK1/2* inhibitor, with IC₅₀s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.

HY-N3828

epi-Eriocalyxin A	Apoptosis ERK JNK	Cancer
epi-Eriocalyxin A (Epieriocalyxin A), a diterpenoid isolated from Isodon eriocalyx, induces colon cancer apoptosis. epi-Eriocalyxin A also inhibits *ERK1/2* and JNK activation, which suppresses Bcl-2 expression.

HY-N0431

Astragaloside IV	MMP ERK JNK	Cancer
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of *ERK1/2* and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

HY-N9725

16-Hydroxycleroda-3,13-dien-15,16-olide 16ξ-Hydroxycleroda-3,13-dien-15,16-olide	Dipeptidyl Peptidase	Metabolic Disease
16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy.

HY-10520

CGP 57380	MNK Apoptosis	Cancer
CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC₅₀ of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.

HY-N6007

Chrysosplenol D	Apoptosis	Cancer Infection Inflammation/Immunology
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities.

HY-101846

AX-15836
ERK Cancer Inflammation/Immunology

AX-15836 is a potent and selective ERK5 inhibitor with an IC₅₀ of 8 nM.

HY-12960

SKLB4771 FLT3-IN-1	FLT3 c-Kit Apoptosis	Cancer
SKLB4771 is a potent and selective Flt3 inhibitor with an IC₅₀ value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue.

HY-152087

DCZ19931	ERK p38 MAPK	Cardiovascular Disease
DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.

HY-100403

Ro 67-7476	mGluR	Cancer
Ro 67-7476 is a potent positive allosteric modulator of mGluR₁ and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC₅₀ of 60.1 nM. Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC₅₀=163.3 nM).

HY-150700

RLX-33	ERK	Metabolic Disease
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC₅₀ values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome.

HY-N6577

Astragaloside VI
EGFR Inflammation/Immunology Neurological Disease

Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.
HY-112570

CC-90003
ERK Cancer

CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.

HY-P3513

β-Neo-Endorphin	ERK MMP	Neurological Disease
β-Neo-Endorphin is an endogenous opioid peptide. β-Neo-Endorphin is a hypothalamic “big” Leu-enkephalin of porcine origin. β-Neo-Endorphin shows activation of the *Erk1/2, MMP-2* and MMP-9.

HY-N10175

Berkeleyacetal C	Fungal Endogenous Metabolite	Inflammation/Immunology
Berkeleyacetal C, a meroterpenoid compound, shows favorable activity of inhibiting nitrogen oxide (NO) production of macrophages stimulated by lipopolysaccharide (LPS). Berkeleyacetal C exerts anti-inflammatory effects via inhibiting NF-κB, ERK1/2 and IRF3 signaling pathways.

HY-139571

Edaxeterkib
ERK Cancer

Edaxeterkib is a potent extracellular signal-regulated kinase (ERK) inhibitor for the research of cancer.
HY-14178

VX-11e
ERK Cancer

VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with K_i < 2 nM.

HY-129566

Withanolide B	ERK Wnt β-catenin	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via *ERK1/2* and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.

HY-N0371

Pachymic acid
3-O-Acetyltumulosic acid
Akt ERK Cancer

Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and ERK signaling pathways.

HY-107753

XRP44X	Ras	Cancer Inflammation/Immunology
XRP44X inhibits Ras-induced transcription activation with the IC₅₀ of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2. XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules.

HY-B1456A

Fenoprofen LILLY-53858	Melanocortin Receptor	Inflammation/Immunology
Fenoprofen (LILLY-53858) is a nonsteroidal anti-inflammatory agent (NSAID). Fenoprofen can be used to to relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. Fenoprofen is an allosteric enhancer for melanocortin receptors. Fenoprofen also increases ERK1/2 activation.

HY-147301

Resomelagon AP1189	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon induces ERK1/2 phosphorylation and Ca²⁺ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research.

HY-101494

Temuterkib LY3214996	ERK	Cancer
Temuterkib (LY3214996) is a highly selective inhibitor of *ERK1* and *ERK2, with IC₅₀* of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-103130

EMD386088	5-HT Receptor	Neurological Disease
EMD386088 is a potent serotonin 6 receptor (5-HT6R) agonist. EMD386088 induces cell death. EMD386088 regulates the activity of ERK1/2. EMD386088 has the potential for the research of alzheimer's disease (AD) and schizophrenia.

HY-137977

DMU-212	ERK Apoptosis	Cancer
DMU-212 is a methylated derivative of Resveratrol (HY-16561), with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of *ERK1/2* protein. DMU-212 has orally active.

HY-W010907

Pamoic acid disodium	GPR35 ERK	Neurological Disease
Pamoic acid disodium is a potent GPR35 agonist with an EC₅₀ value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates *ERK1/2* with EC₅₀ values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect.

HY-113916

Onalespib lactate	HSP	Cancer
Onalespib lactate is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor with an K_d value of 0.71 nM. Onalespib lactate inhibits the proliferation, survival and migration. Onalespib lactate decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib lactate shows antitumor activity. Onalespib lactate has the potential for the research of non-small cell lung cancer (NSCLC).

HY-107640

WAY-170523	MMP	Cancer
WAY-170523 is a potent and selective MMP-13 (matrix metalloproteinase-13) inhibitor, with an IC₅₀ of 17 nM. WAY-170523 can directly attenuate ERK1/2 phosphorylation. WAY-170523 inhibits the invasion of PC-3 cells, can be used for prostate cancer research.

HY-120006A

(rel)-AR234960	ERK	Cardiovascular Disease
(rel)-AR234960 is an active relative configuration of AR234960. AR234960, a non-peptide MAS (a G protein-coupled receptor) agonist, increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts.

HY-114453

SHP389
SHP2 Phosphatase Others

SHP389 is an allosteric SHP2 inhibitor, with an IC₅₀ of 36 nM for both SHP2 and p-ERK.

HY-146672

ITK inhibitor 6	Itk	Cancer
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC₅₀s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities.

HY-14188

Amiodarone hydrochloride	Potassium Channel Autophagy	Cardiovascular Disease Cancer
Amiodarone hydrochloride, a benzofuran-based Class III antiarrhythmic agent, inhibits WT outwardIhERG tails with an IC₅₀ of ∼45 nM. Amiodarone hydrochloride induces cell proliferation and myofibroblast differentiation via *ERK1/2* and p38 MAPK signaling in fibroblasts. Amiodarone hydrochloride can be used in the research of both supraventricular and ventricular arrhythmias.

HY-14340

WAY-181187 SAX-187	5-HT Receptor	Neurological Disease
WAY-181187 (SAX-187) is a potent and selective full 5-HT6 receptor agonist with a K_i of 2.2 nM and an EC₅₀ of 6.6 nM. WAY181187 mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.

HY-147855

ACA-28	ERK Apoptosis	Cancer
ACA-28 (compound 2a) is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth by inducing apoptosis with ERK hyperactivation ACA-28 inhibits cell growth of melanoma cells (SK-MEL-28) and normal melanocytes (NHEM), with IC₅₀ values of 5.3 and 10.1 μM, respectively.

HY-13241

Ralimetinib dimesylate LY2228820 dimesylate	p38 MAPK Autophagy Apoptosis	Cancer Inflammation/Immunology
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-13905

Flumatinib mesylate HHGV678 mesylate	Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀ values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model.

HY-N10047

7,8-Didehydrocimigenol	NF-κB PPAR	Cardiovascular Disease
7,8-Didehydrocimigenol is an active triterpenoid that can be isolated from Cimicifugae rhizoma. 7,8-Didehydrocimigenol inhibits TNF-α-induced VCAM-1 expression, inhibits NF-kB activity and phosphorylation of ERK1/2 and Akt, increases PPAR-γ expression. 7,8-Didehydrocimigenol can be used for the research of cardiovascular disorders such as atherosclerosis.

HY-110366

WAY-181187 oxalate SAX-187 oxalate	5-HT Receptor	Neurological Disease
WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a K_i of 2.2 nM and an EC₅₀ of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.

HY-N1987

Cucurbitacin IIb	Apoptosis	Inflammation/Immunology
Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α.

HY-B1456AS

Fenoprofen-13C6(sodium salt hydrate)	Isotope-Labeled Compounds Melanocortin Receptor	Inflammation/Immunology
Fenoprofen-¹³C₆ (sodium hydrate) is the ¹³C labeled Fenoprofen (HY-B1456A). Fenoprofen is a nonsteroidal anti-inflammatory agent (NSAID). Fenoprofen can be used to to relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. Fenoprofen is an allosteric enhancer for melanocortin receptors. Fenoprofen also increases ERK1/2 activation[1][2][3].

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-122404

Xantocillin Xanthocillin X	MEK ERK Autophagy	Cancer
Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the *MEK/ERK* pathway.

HY-126477

NNK	Endogenous Metabolite	Cancer
NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser⁷⁰ and c-Myc at Thr⁵⁸ and Ser⁶² through activation of both *ERK1/2* and PKCα. NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure.

HY-14188S

Amiodarone-d4 hydrochloride	Potassium Channel Autophagy	Cardiovascular Disease Cancer
Amiodarone-d₄ (hydrochloride) is the deuterium labeled Amiodarone hydrochloride. Amiodarone hydrochloride, a benzofuran-based Class III antiarrhythmic agent, inhibits WT outwardIhERG tails with an IC50 of ∼45 nM[1]. Amiodarone hydrochloride induces cell proliferation and myofibroblast differentiation via ERK1/2 and p38 MAPK signaling in fibroblasts[2]. Amiodarone hydrochloride can be used in the research of both supraventricular and ventricular arrhythmias[1].

HY-16697

CID 16020046	GPR55	Cancer
CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC₅₀ of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca²⁺ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function.

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-13241A

Ralimetinib LY2228820	p38 MAPK Autophagy	Cancer Inflammation/Immunology
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-N2329

Piperlongumine Piplartine	ERK Reactive Oxygen Species Autophagy Apoptosis Bacterial Ferroptosis	Cancer Infection Cardiovascular Disease
Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome.

HY-150587

Anti-inflammatory agent 31	ERK NF-κB	Inflammation/Immunology
Anti-inflammatory agent 31 (enone 17) is a kind of andrographolide derivatives, is a anti-inflammatory agent. Anti-inflammatory agent 31 inhibits NF-κB activation by upstream blockade of PI3K/Akt and ERK1/2 MAPK activation. Anti-inflammatory agent 31 shows recovery effective of the intracellular GSH levels and protective effect on liver.

HY-112082

BAY885
ERK Cancer

BAY885 is a highly potent and selective ERK5 inhibitor with an IC₅₀ of 35 nM. BAY885 shows weak inhibition on others kinases.

HY-P4159

Endothelin-1 (1-31) (Human)	ERK	Cardiovascular Disease
Endothelin-1 (1-31) (Human) is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) is derived from the selective hydrolysis of big ET-1 by chymase.

HY-P3750

Methionyl-Lysyl-Bradykinin Met-Lys-Bradykinin	Bradykinin Receptor	Endocrinology Cardiovascular Disease
Methionyl-Lysyl-Bradykinin (Met-Lys-Bradykinin), a Bradykinin (HY-P0206) analogue, is a kinin.

HY-P4159B

Endothelin-1 (1-31) (Human) acetate	ERK	Cardiovascular Disease
Endothelin-1 (1-31) (Human) acetate is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) acetate is derived from the selective hydrolysis of big ET-1 by chymase.

HY-P4159A

Endothelin-1 (1-31) (Human) TFA	ERK	Cardiovascular Disease
Endothelin-1 (1-31) (Human) TFA is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) TFA is derived from the selective hydrolysis of big ET-1 by chymase.

HY-N0774

Isofraxidin	COX MMP Toll-like Receptor (TLR)	Inflammation/Immunology
Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits MMP-7 expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of *ERK1/2* in hepatoma cells. Isofraxidin attenuates the expression of iNOS and COX-2, Isofraxidinalso inhibits TLR4/myeloid differentiation protein-2 (MD-2) complex formation.

HY-N1818

Deoxysappanone B 3-Deoxysappanone B	p38 MAPK	Inflammation/Immunology Neurological Disease
Deoxysappanone B (3-Deoxysappanone B) is a homoisoflavone compound isolated from Caesalpinia sappan L (Lignum Sappan). Deoxysappanone B has anti-neuroinflammatory and neuroprotective effects and inhibits the production of neuroinflammatory mediators by blocking the IκB kinase (IKK)-NF-κB and p38/ERK MAPK pathways. Deoxysappanone B can be used in disease studies of neuritis and inflammation-related neurological damage.

HY-111083

ML191 CID23612552	GPR55	Others
ML-191 is an antagonist of GPR55. It inhibits GPR55 signaling induced by lysophosphatidylinositol (EC₅₀=1.076 µM in U2OS cells overexpressing GPR55). ML-191 inhibits LPI-induced phosphorylation of ERK1/2 (IC₅₀=328 nM) and receptor-dependent translocation of PKCβII when used at a concentration of 30 µM.

HY-N0265

Asperosaponin VI	Caspase Apoptosis	Cardiovascular Disease
Asperosaponin VI, A saponin component from Dipsacus asper, induces osteoblast differentiation through BMP‐2/p38 and ERK1/2 pathway. Asperosaponin Ⅵ inhibits apoptosis in hypoxia-induced cardiomyocyte by increasing the Bcl-2/Bax ratio and decreasing active caspase-3 expression, as well as enhancing of p-Akt and p-CREB.

HY-12056

BIX02189
MEK ERK Cancer

BIX02189 is a potent and selective MEK5 inhibitor with an IC₅₀ of 1.5 nM. BIX02189 also inhibits ERK5 catalytic activity with an IC₅₀ of 59 nM.

HY-151379

EM127	Histone Methyltransferase	Cancer
EM127 (compound 11c) is a SMYD3 covalent inhibitor with high selectivity, high affinity (K_D=13 μM) and site-specificity. EM127 effectively inhibits *ERK1/2* phosphorylation and reduces transcriptional regulation of SMYD3 target genes. EM127 effectively and prolongedly impairs methyltransferase activity. EM127 can be used in cancer research, particularly in SMYD3 positive tumours.

HY-12055

BIX02188
MEK ERK Cancer

BIX02188 is a potent MEK5-selective inhibitor with an IC₅₀ of 4.3 nM. BIX02188 inhibits ERK5 catalytic activity, with an IC₅₀ of 810 nM.
HY-111483

Tizaterkib
AZD0364
ERK Cancer

Tizaterkib (AZD0364) is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC₅₀ of 0.6 nM.

HY-19700

trans-Zeatin	MEK ERK Endogenous Metabolite	Others
trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced *MEK/ERK* activation.

HY-104047

LM22B-10
Trk Receptor Akt ERK Neurological Disease

LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.

HY-N11439

Albanol B	CDK Akt ERK Apoptosis Bacterial	Cancer Infection Neurological Disease
Albanol B is an arylbenzofuran derivative which can be isolated from mulberries. Albanol B exhibits anti-Alzheimer's disease, anti-bacterial and antioxidant activities. Albanol B inhibits cancer cells proliferation, down-regulates CDK1 expression. Albanol B also induces cell cycle arrest at G2/M and apoptosis. And Albanol B induces mitochondrial ROS production and increases the phosphorylation levels of AKT and *ERK1/2*.

HY-152168

NSC 295642	PERK Phosphatase	Cancer
NSC 295642 is a phosphatase inhibitor. NSC 295642 can significantly increase *phospho-Erk* cytonuclear differences in intact cells. NSC 295642 can be used for the research of cancer.

HY-19696

Tauroursodeoxycholate Tauroursodeoxycholic acid; TUDCA; UR 906	ERK Caspase Endogenous Metabolite Apoptosis	Cancer
Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits *ERK*.

HY-14985

BAY 61-3606 dihydrochloride	Syk Apoptosis	Inflammation/Immunology Cancer
BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a K_i of 7.5 nM an IC₅₀ of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.

HY-122214

AC-73	Autophagy	Cancer
AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the *CD147*/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells. AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells.

HY-76474

BAY 61-3606	Syk Apoptosis	Cancer Inflammation/Immunology
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a K_i of 7.5 nM and an IC₅₀ of 10 nM. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.

HY-N2484

Methylnissolin Astrapterocarpan	PDGFR ERK	Cardiovascular Disease
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC₅₀ of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the *ERK1/2* MAP kinase cascade.

HY-113509

Lipoxin A4 LXA4	Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC₅₀ value of 25.74 nM.

HY-19696A

Tauroursodeoxycholate sodium Tauroursodeoxycholic acid sodium; TUDCA sodium; UR 906 sodium	ERK Caspase Apoptosis Endogenous Metabolite	Cancer
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits *ERK*.

HY-N1966

(E)-Osmundacetone	p38 MAPK JNK ERK	Neurological Disease
(E)-Osmundacetone is the isomer of Osmundacetone. Osmundacetone significantly suppresses the phosphorylation of MAPKs, including JNK, ERK, and p38 kinases. Osmundacetone has a neuroprotective effect against oxidative stress.

HY-N2270

Chicanine	p38 MAPK ERK IKK	Inflammation/Immunology
Chicanine is a lignan compound of Schisandra chinesis, inhibits LPS-induced phosphorylation of p38 MAPK, ERK 1/2 and IκB-α, with anti-inflammatory activity.

HY-13810

PF-04880594
Raf Cancer

PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity.
HY-144690

D5261
Trk Receptor Cancer

D5261 is a potent, type III allosteric tropomyosin-related kinase A (TrkA) inhibitor.

HY-110318

VUF11207 fumarate	CXCR	Cancer Inflammation/Immunology
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting *ERK* phosphorylation.

HY-18318

Takeda-6D	Raf VEGFR PERK	Cancer
Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC₅₀ values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of *ERK1/2* phosphorylation. Takeda-6D shows antitumor activity.

HY-116461

ML-184 CID2440433	GPR55	Neurological Disease
ML-184 (CID2440433) is a selective GPR55 agonist with an EC₅₀ of 250 nM and exhibits >100-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-184 induces phosphorylation of ERK1/2 and translocation of PKCβII to the plasma membrane by activating GPR55. ML-184(CID2440433) increases proliferation of neural stem cells and promotes neuronal differentiation in vitro.

HY-P3418A

CKLF1-C27 TFA	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates *ERK1/2* pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research.

HY-12927

SX-517	CXCR	Inflammation/Immunology
SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca²⁺ flux (IC₅₀=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC₅₀=60 nM) and *ERK1/2* phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model.

HY-P3418

CKLF1-C27	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates *ERK1/2* pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research.

HY-N6264

26-Deoxyactein	Aryl Hydrocarbon Receptor ERK	Metabolic Disease
26-Deoxyactein is a constituent isolated from Cimicifuga racemosa, prevents TCDD-induced osteoblasts damage. 26-Deoxyactein inhibits increased AhR, CYP1A1 and ERK levels.

HY-134811

KRAS G12D inhibitor 1
Ras Cancer

KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC₅₀ of 0.8 nM for KRAS G12D-mediated ERK phosphorylation.

HY-N2051

Zeylenone	Apoptosis	Cancer
Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.

HY-N6826

Asatone	NF-κB	Inflammation/Immunology
Asatone is an active component isolated from Radix et Rhizoma Asari, with anti-inflammatory effect via activation of NF-κB and donwn regulation of p-MAPK (ERK, JNK and p38) pathways.

HY-113599

Isoprocurcumenol	EGFR ERK Akt	Others
Isoprocurcumenol is a guaiane type sesquiterpene, that can be isolated from Curcuma comosa. Isoprocurcumenol can activate EGFR signaling. Isoprocurcumenol increases the phosphorylation of *ERK* and AKT. Isoprocurcumenol promotes the proliferation of keratinocytes.

HY-13404A

Capmatinib dihydrochloride INC280 dihydrochloride; INCB28060 dihydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase.

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Cancer Infection Inflammation/Immunology
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, *Erk1/2* and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).

HY-145384

ROC-0929	Phospholipase	Inflammation/Immunology
ROC-0929 (compound 13a) is a potent and selective inhibitor of secreted phospholipases A₂ (sPLA₂s) with an IC₅₀ of 80 nM, specially targeting hGX. ROC-0929 inhibits the phosphorylation of *ERK1/2* and p-38. Secreted phospholipases A2 (sPLA2s) are a family of disulfide-rich, Ca²⁺-dependent enzymes that hydrolyze the sn-2 position of glycero-phospholipids to release a fatty acid and a lysophospholipid. ROC-0929 has the potential for researching inflammation related diseases.

HY-13404C

Capmatinib dihydrochloride hydrate INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase.

HY-13404

Capmatinib INC280; INCB28060	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase.

HY-13404B

Capmatinib hydrochloride INC280 hydrochloride; INCB-28060 hydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase.

HY-32718

Pelitinib EKB-569; WAY-EKB 569	EGFR Src	Cancer
Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively.

HY-17600S

Acalabrutinib-d4 ACP-196-d₄	Btk	Cancer
Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor[1].

HY-17600

Acalabrutinib ACP-196	Btk	Cancer
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-17437A

Mefloquine hydrochloride Mefloquin hydrochloride	Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase	Cancer Infection Metabolic Disease Inflammation/Immunology
Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research.

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

HY-W011428

Olomoucine	CDK	Others
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 µM), CDK/p35 kinase (IC₅₀=3 µM) and ERK1/p44 MAP kinase (IC₅₀=25 µM). Olomoucine regulates cell cycle and shows anti-melanin tumor activity.

HY-120793

CMC2.24 TRB-N0224	Ras Apoptosis MMP	Cancer Inflammation/Immunology
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC₅₀s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis.

HY-12028

PD98059	MEK ERK Aryl Hydrocarbon Receptor Autophagy	Cancer
PD98059 is a potent and selective MEK inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC₅₀ of 2-7 µM) and MEK2 (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a *ERK1/2* signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy.

HY-151431

Nrf2/HO-1 activator 2	Keap1-Nrf2 Reactive Oxygen Species ERK Akt JNK	Neurological Disease
Nrf2/HO-1 activator 2 (compound 13m), difluoro-substituted derivative, is a potent Nrf2/HO-1 activator. Nrf2/HO-1 activator 2 has neuroprotective and antioxidant effects through the Nrf2/HO-1 pathway mediated by phosphorylation of ERK1/2, JNK, or Akt in PC12 cells. Nrf2/HO-1 activator 2 can be used in the research of Parkinson's disease (PD).

HY-113509S

Lipoxin A4-d5 LXA4-d₅	Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

HY-19696S

Tauroursodeoxycholate-d5	ERK Caspase Endogenous Metabolite Apoptosis	Cancer
Tauroursodeoxycholate-d₅ is the deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-19700S

trans-Zeatin-d5	MEK ERK Endogenous Metabolite	Others
trans-Zeatin-d₅ is deuterium labeled trans-Zeatin. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.

HY-19696S1

Tauroursodeoxycholate-d4 Tauroursodeoxycholic acid-d₄; TUDCA-d₄; UR 906-d₄	ERK Caspase Endogenous Metabolite Apoptosis	Cancer
Tauroursodeoxycholate-d₄ is deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-19696S2

Tauroursodeoxycholate-d4-1 Tauroursodeoxycholic acid-d₄-1; TUDCA-d₄-1; UR 906-d₄-1	ERK Caspase Endogenous Metabolite Apoptosis
Tauroursodeoxycholate-d₄-1 is the deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and *ERK*. Abituzumab can be used in cancer research, particularly in prostate cancer.

HY-19696AS

Tauroursodeoxycholate-d4 sodium Tauroursodeoxycholic acid-d₄ (sodium); TUDCA-d₄ (sodium); UR 906-d₄ (sodium)	ERK Caspase Apoptosis Endogenous Metabolite	Cancer
Tauroursodeoxycholate-d₄ (sodium) is the deuterium labeled Tauroursodeoxycholate sodium. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-108543

NSC 95397	Phosphatase Apoptosis	Cancer
NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)). NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.

HY-N6674

Diazepinomicin ECO-4601; TLN-4601; BU 4664L	Ras Apoptosis	Cancer
Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.

HY-B0444A

Maprotiline	Autophagy	Cancer Neurological Disease
Maprotiline is a highly selective noradrenergic reuptake blocker, has strong antidepressant efficacy. Maprotiline induces cancer cells apoptosis by targeting *ERK* signaling pathway and CRABP1. Maprotiline restrains cell proliferation and metastasis, exhibits anticancer effect.

HY-N1504

Loureirin B	PAI-1 Potassium Channel ERK JNK	Metabolic Disease
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of *ERK* and JNK, and has anti-diabetic activity.

HY-10579

Pluripotin SC1	Ribosomal S6 Kinase (RSK) ERK	Cancer
Pluripotin is a dual inhibitor of *ERK1* and RasGAP with K_Ds of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC₅₀s of 0.5, 2.5, 3.3, and 10.0 µM, respectively.

HY-135985

DCLK1-IN-1	Others	Cancer
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC₅₀: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1⁺ pancreatic ductal adenocarcinoma (PDAC).

HY-104066A

Theliatinib tartrate Xiliertinib tartrate; HMPL-309 tartrate	EGFR	Cancer
Theliatinib (Xiliertinib) tartrate is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases.

HY-147405

Tinlorafenib PF-07284890; ARRY-461	Raf	Cancer
Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC₅₀s of 4.25 and 2.7 nM for BRAF^V600E/V600K respectively. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies.

HY-105226

CI-988 PD134308	Cholecystokinin Receptor	Cancer Neurological Disease
CI-988 (PD134308) is a potent, selective and orally active CCK2R (cholecystokinin 2 receptor) antagonist with an IC₅₀ of 1.7 nM for mouse cortex CCK2. CI-988 shows >1600-fold selectivity for CCK2 over CCK1 receptor. CI-988 has anxiolytic and anti-tumor effects.

HY-104066

Theliatinib Xiliertinib; HMPL-309	EGFR	Cancer
Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases.

HY-146195

MAPK-IN-1	Toll-like Receptor (TLR) p38 MAPK JNK ERK Cholinesterase (ChE)	Inflammation/Immunology Neurological Disease
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC₅₀ of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research.

HY-N7108

7-Hydroxyflavone	ERK Keap1-Nrf2	Inflammation/Immunology
7-Hydroxyflavone is a flavonoid isolated from Clerodendrum phlomidis, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway.

HY-N2375

L-Quebrachitol	Wnt β-catenin	Metabolic Disease
L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway.

HY-N0226

Epiberberine	Cholinesterase (ChE) Beta-secretase	Metabolic Disease Neurological Disease
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Epiberberinecan be used for the research of diabetic disease.

HY-N0226A

Epiberberine chloride	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species	Metabolic Disease Neurological Disease
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease. Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Epiberberine has the potential effect in the research of diabetic disease.

HY-100489

TBHQ tert-Butylhydroquinone	Keap1-Nrf2 ERK Autophagy Apoptosis Ferroptosis	Cancer
TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) is also an *ERK* activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma.

HY-N8303

Gardenin A	ERK PAK	Inflammation/Immunology Neurological Disease
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating *MAPK/ERK, PKC, and PKA*, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects.

HY-P4136

Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits *ERK* activation with an IC₅₀ of 10 μM.

HY-108559

L-161982	Prostaglandin Receptor	Inflammation/Immunology
L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.

HY-N3806

Enniatin B	Acyltransferase ERK	Cancer Infection Cardiovascular Disease
Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of *ERK* (p44/p42).

HY-13076

CHIR-98014	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC₅₀s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.

HY-N0809

Sesamolin	p38 MAPK JNK Caspase	Metabolic Disease Neurological Disease
Sesaminol, isolated from Sesamum indicum, has antioxidative activity, Sesaminol inhibits lipid peroxidation and shows neuroprotection effect. Sesaminol potently inhibits MAPK cascades by preventing phosphorylation of JNK, p38 MAPKs, and caspase-3 but not ERK-MAPK expression.

HY-103211

L748337	Adrenergic Receptor	Cancer Metabolic Disease Cardiovascular Disease
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The K_i values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively. L748337 couples predominantly to G_i to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC₅₀ value of 11.6. L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases.

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells.

HY-101246

RPI-1	RET	Cancer
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity.

HY-15615A

Dordaviprone TIC10; ONC-201	TNF Receptor Apoptosis	Cancer
Dordaviprone (TIC10) is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL. Dordaviprone can cross the blood-brain barrier.

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of *ERK2* by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable.

HY-50055

EtDO-P4	Others	Cancer
EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma.

HY-117596

UNC569	TAM Receptor	Cancer
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

HY-148117

MD13	PROTACs Macrophage migration inhibitory factor (MIF)	Cancer
MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a K_i of 71 nM. MD13 can be used for cancer research.

HY-32736

Triptonide NSC 165677; PG 492	Wnt β-catenin Apoptosis Autophagy	Cancer Inflammation/Immunology
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC₅₀ of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.

HY-12736

GSK143	Syk PERK	Cancer Inflammation/Immunology
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC₅₀=7.1). GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice.

HY-12736A

GSK143 dihydrochloride	Syk PERK	Cancer Inflammation/Immunology
GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC₅₀=7.1). GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice.

HY-14443

XMD8-92	ERK Epigenetic Reader Domain	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity.

HY-123952

RTC-5 TRC-382	EGFR	Cancer
RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.

HY-N0745

Senkyunolide I	Caspase	Inflammation/Immunology
Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.

HY-N2450

Sulforaphene	Apoptosis EGFR ERK NF-κB	Cancer
Sulforaphene, isolated from radish seeds, exhibits an ED₅₀ against velvetleaf seedlings approximately 2 x 10^-4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, *p-ERK1/2, NF‐κB* and other signals.

HY-N2208

4-Hydroxylonchocarpin	p38 MAPK	Cancer Infection Metabolic Disease Inflammation/Immunology
4-Hydroxylonchocarpin is a chalcone compound from an extract of Psoralea corylifolia. 4-Hydroxylonchocarpin increases phosphorylation of p38 MAPK, JNK and ERK. 4-Hydroxylonchocarpin has diverse pharmacological activities, including antibacterial, antifungal, anticancer, antireverse transcriptase, antitubercular, antimalarial, anti-inflammatory and antioxidant activities.

HY-132601

Cobomarsen MRG-106	MicroRNA	Cancer
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including JAK/STAT, *MAPK/ERK* and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma.

HY-110198

ONO-8130	Prostaglandin Receptor PERK	Inflammation/Immunology
ONO-8130 is an orally active and selective prostanoid EP1 receptor antagonist. ONO-8130 blocks phosphorylation of *ERK* in the L6 spinal cord. ONO-8130 relieves bladder pain in mice with cyclophosphamide-induced cystitis. ONO-8130 can be used for interstitial cystitis research.

HY-147183

JBJ-09-063	EGFR	Cancer
JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 can be used for researching EGFR-mutant lung cancer.

HY-147183A

JBJ-09-063 TFA	EGFR	Cancer
JBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 TFA effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 TFA is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 TFA can be used for researching EGFR-mutant lung cancer.

HY-147183B

JBJ-09-063 hydrochloride	EGFR	Cancer
JBJ-09-063 hydrochloride is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 hydrochloride effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 hydrochloride is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 hydrochloride can be used for researching EGFR-mutant lung cancer.

HY-124514

UC-857993	Ras ERK	Cancer
UC-857993 is a selective SOS1-Ras inhibitor (K_d=14.7 μM, His₆-SOS1_cat), suppressing catalytic activity. UC-857993 also inhibits *ERK* and Ras activation, suppresses the growth of mouse embryonic fibroblasts (MEFs).

HY-100851A

LY-272015 hydrochloride	5-HT Receptor	Cardiovascular Disease
LY-272015 hydrochloride is an orally active, specific 5-HT_2B receptor antagonist. LY-272015 hydrochloride completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86. LY-272015 hydrochloride is antihypertensive in Deoxycorticosterone Acetate (DOCA)-salt-hypertensive rats.

HY-126307

Urolithin B	NF-κB JNK ERK Akt AMPK Endogenous Metabolite	Inflammation/Immunology
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, *ERK, and Akt, and enhances the phosphorylation of AMPK*. Urolithin B is also a regulator of skeletal muscle mass.

HY-N2963

Broussonin E	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase	Inflammation/Immunology
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the *ERK* and p38 MAPK and enhancing JAK2-STAT3 signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis.

HY-N4042

Hirsutenone	PI3K ERK	Cancer Inflammation/Immunology
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and *ERK1* in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity.

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2.

HY-B0185B

Lidocaine hydrochloride hydrate Lignocaine hydrochloride hydrate	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of *MEK/ERK* and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia.

HY-101364A

CHPG sodium salt	mGluR NF-κB ERK Akt	Inflammation/Immunology Neurological Disease
CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the *ERK* and Akt signaling pathways..

HY-B0185

Lidocaine Lignocaine	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of *MEK/ERK* and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.

HY-N3071

Picrasidine I	Apoptosis Reactive Oxygen Species	Inflammation/Immunology
Picrasidine I is an anti-inflammatory and anti-osteoclastogenic dimeric alkaloid that can be isolated from Picrasma quassioides. Picrasidine I inducs cell cycle arrest, and triggers cell apoptosis by downregulats *ERK* and Akt pathways. Picrasidine I inhibits the activation of MAPKs, NF-κB and ROS generation, and suppresses the expression of c-Fos and NFATc1.

HY-142283AS

Dosimertinib mesylate	EGFR	Cancer
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-101364

CHPG	mGluR NF-κB ERK Akt	Inflammation/Immunology Cardiovascular Disease
CHPG is a selective mGluR5 agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the *ERK* and Akt signaling pathways.

HY-N3298

Meranzin	Adrenergic Receptor	Neurological Disease Cardiovascular Disease
Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway. Meranzin has the potential for the prevention of the comorbidity of atherosclerosis and depression.

HY-N6704

Enniatin A1	ERK Apoptosis	Cancer
Enniatin A1 isolated from Fusarium mycotoxins is a cyclic hexadepsipeptide consisting of alternating D-α-hydroxyisovaleric acids and N-methyl-L-amino acids. Enniatin A1 possesses anticarcinogenic properties by induction of apoptosis and disruption of *ERK* signalling pathway. Enniatin A1 inhibits ACAT with an IC₅₀ of 49 μM in rat liver microsomes.

HY-149205

CXJ-2	PI3K ERK	Inflammation/Immunology
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the *PI3K/ERK* pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy.

HY-N0104

Curcumol (-)-Curcumol	Apoptosis	Cancer
Curcumol ((-)-Curcumol), a bioactive sesquiterpenoid, possesses numerous pharmacological activities like anticancer, antimicrobial, antifungal, antiviral, and antiinflammatory. Curcumol is a potent inducer of apoptosis in numerous cancer cells via targeting key signaling pathways as MAPK/ERK, PI3K/Akt and NF-κB which are generally deregulated in several cancers.

HY-15779

K145	SphK Apoptosis	Cancer
K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC₅₀ of 4.3 µM and a K_i of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity.

HY-15779A

K145 hydrochloride	SphK Apoptosis	Cancer
K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC₅₀ of 4.3 µM and a K_i of 6.4 µM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis and has potently antitumor activity.

HY-114683

KS370G	Others	Cardiovascular Disease
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy.

HY-143293

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer.

HY-N7110

6-Hydroxyflavone	Akt ERK JNK	Inflammation/Immunology
6-Hydroxyflavone is a naturally occurring flavone, with anti-inflammatory activity. 6-Hydroxyflavone exhibits inhibitory effect towards bovine hemoglobin (BHb) glycation. 6-Hydroxyflavone can activate AKT, ERK 1/2, and JNK signaling pathways to effectively promote osteoblastic differentiation. 6-Hydroxyflavone inhibits the LPS-induced NO production .

HY-B0185A

Lidocaine hydrochloride Lignocaine hydrochloride	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of *MEK/ERK* and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor.

HY-P4052

Pinealon	ROS Kinase	Neurological Disease
Pinealon is a 3-amino acid peptide and shows neuroprotective properties. Pinealon prevents reactive oxygenspecies (ROS) accumulation and supressesthe activation of ERK 1/2. Pinealon has the ability to stimulate the functional activity of the main cellular elements of brain tissue, reduce the level of spontaneous cell death. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.

HY-N1930

(-)-Hinesol Hinesol	Apoptosis	Cancer
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer.

HY-10254

Mirdametinib PD0325901; PD325901	MEK Autophagy Apoptosis	Cancer
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts.

HY-B0185AS

Lidocaine-d10 hydrochloride	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-N0678

Icaritin Anhydroicaritin	Autophagy Apoptosis	Cancer
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate *MAPK/ERK/JNK* and JAK2/STAT3 /AKT signalings, also enhances osteogenesis^[3.

HY-150054

G12Si-5	Ras	Cancer
G12Si-5 is a covalent inhibitor of the G12S mutant of K-Ras (K_i: 26 μM). G12Si-5 binds with the S-IIP domain and suppresses oncogenic signaling. G12Si-5 reduces phospho-ERK level in KRAS G12S mutated cells.

HY-101446

HIOC	Trk Receptor ERK Apoptosis	Neurological Disease
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates *TrkB/ERK* pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration.

HY-P99275

Patritumab Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, *ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

HY-B0185S1

Lidocaine-d10	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-18285

Longdaysin	Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and *ERK2* with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively.

HY-128463

N-tert-Butyl-α-phenylnitrone	COX Reactive Oxygen Species	Metabolic Disease Inflammation/Immunology Neurological Disease
N-tert-Butyl-α-phenylnitrone is a nitrone-based free radical scavenger that forms nitroxide spin adducts. N-tert-Butyl-α-phenylnitrone inhibits COX2 catalytic activity. N-tert-Butyl-α-phenylnitrone has potent ROS scavenging, anti-inflammatory, neuroprotective, anti-aging and anti-diabetic activities, and can penetrate the blood-brain barrier.

HY-126390

(E/Z)-BCI NSC 150117	Phosphatase Apoptosis	Cancer Inflammation/Immunology
(E/Z)-BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z)-BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway.

HY-150054A

G12Si-5 formic	Ras	Cancer
G12Si-5 formic is a covalent inhibitor of the G12S mutant of K-Ras (K_i: 26 μM). G12Si-5 formic binds with the S-IIP domain and suppresses oncogenic signaling. G12Si-5 formic reduces phospho-ERK level in KRAS G12S mutated cells.

HY-124421

5F-203 NSC-703786	Aryl Hydrocarbon Receptor	Others
5F-203 (NSC-703786) is a cytotoxic molecule that forms DNA adducts and cell cycle arrest. 5F-203 induces aryl hydrocarbon receptor (AhR) signaling and elevates expression of CYP1A1. 5F-203 also increases the levels of reactive oxygen species as well as activates JNK, ERK, and p38.

HY-B0185AS1

Lidocaine-d6 hydrochloride Lignocaine-d₆ hydrochloride	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
Lidocaine-d₆ (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

HY-B0185S

Lidocaine-d10 N-Oxide	Sodium Channel MEK ERK NF-κB Apoptosis	Cancer Cardiovascular Disease
N-Oxide Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-107426

Verrucarin A Muconomycin A	Apoptosis Reactive Oxygen Species	Cancer
Verrucarin A (Muconomycin A), a Type D macrocyclic mycotoxin derived from the pathogen fungus Myrothecium verrucaria, is an inhibitor of protein synthesis. Verrucarin A inhibits growth of leukemia cell lines and activates caspases and apoptosis and inflammatory signaling in macrophages. Verrucarin A effectively increased the phosphorylation of p38 MAPK and diminished the phosphorylation of ERK/Akt. Verrucarin A caused cell cycle deregulation through the induction of p21 and p53.

HY-W010983

SC-236	COX PPAR Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
SC-236 is an orally active COX-2 specific inhibitor (IC₅₀ = 10 nM) and a PPARγ agonist. SC-236 suppresses activator protein-1 (AP-1) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model.

HY-115907

K20	Ras ERK Apoptosis	Cancer
K20 is a potent and selective KRas G12C inhibitor with an IC₅₀ of 1.16 µM. K20 shows anticancer activity in H358 cells (IC₅₀= 0.78 µM). K20 decreases the levels of phosphorylated *Erk* and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity.

HY-151802

CPUL1	TrxR	Cancer
CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated *ERK/JNK* signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective.

HY-147513

AKT-IN-12	Akt Apoptosis	Cancer
AKT-IN-12 (compound 3e) is a potent Akt kinase inhibitor with an IC₅₀ value of 0.55 μM. AKT-IN-12 induces G0/G1 cell cycle arrest and apoptosis. AKT-IN-12 also inhibits p-AKT, p-ERK, and activates p-JNK, JNK. AKT-IN-12 can be used for researching leukemia.

HY-112701

CCR6 inhibitor 1	CCR	Cancer Inflammation/Immunology Endocrinology
CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC₅₀s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC₅₀, > 30000 nM), and CCR7 (IC₅₀, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation. CCR6 inhibitor 1 is used in the research of autoimmune diseases and cancer.

HY-146476

KRAS inhibitor-18	Ras	Cancer
KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC₅₀ of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC₅₀s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-146543

KRAS inhibitor-13	Ras	Cancer
KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC₅₀s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-146533

KRAS inhibitor-12	Ras	Cancer
KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC₅₀s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-146545

KRAS inhibitor-15	Ras	Cancer
KRAS inhibitor-15 (compound 3-19) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.954 µM. KRAS inhibitor-15 shows p-ERK inhibition activities with IC₅₀s of 2.03, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-15 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-146546

KRAS inhibitor-16	Ras	Cancer
KRAS inhibitor-16 (compound 3-11) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.457 µM. KRAS inhibitor-16 shows p-ERK inhibition activities with IC₅₀s of 3.06, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-16 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-146475

KRAS inhibitor-17	Ras	Cancer
KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC₅₀ of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC₅₀s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-146544

KRAS inhibitor-14	Ras	Cancer
KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC₅₀s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-134813

MRTX1133	Ras	Cancer
MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations.

HY-129156

HS-1793
Apoptosis Cancer

HS-1793 is a Resveratrol (HY-16561) analogue with antitumor activities in a variety of cancer cell lines. HS-1793 induces cell apoptosis.

HY-N0619

Mulberroside A	TNF Receptor Interleukin Related Tyrosinase	Inflammation/Immunology
Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM.

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy.

HY-118140

ZCZ011	Cannabinoid Receptor	Inflammation/Immunology Neurological Disease
ZCZ011 is a potent and brain penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain.

HY-100035

PT-262	ROCK ERK CDK Apoptosis	Cancer
PT-262 is a potent ROCK inhibitor with an IC₅₀ value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the *ERK* and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity.

HY-N6796

Manumycin A	Farnesyl Transferase Ras Apoptosis Phospholipase	Cancer Infection
Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling. Manumycin A is a nSMase inhibitor (EC₅₀=0.25 μM).

HY-144323

YF135	PROTACs PERK	Cancer
YF135 is an efficient and reversible-covalent KRAS^G12C PROTAC. YF135 is designed and synthesized by tethering KRAS G12C inhibitor 48 (compound 6d) as the ligand, and basing on the scaffold of MRTX849 linkage VHL ligand. YF135 significantly induces the degradation of KRAS^G12C in a reversible manner and decreases phospho-ERK level through the E3 ligase VHL mediated proteasome pathway.

HY-119016A

SK1-I hydrochloride BML-258 hydrochloride	SphK	Cancer
SK1-I hydrochloride (BML-258 hydrochloride), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of 10 µM. SK1-I hydrochloride shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I hydrochloride enhances autophagy and has antitumor activity.

HY-N0498

Nitidine chloride	Parasite Apoptosis STAT Topoisomerase ERK FAK p38 MAPK NF-κB	Cancer Inflammation/Immunology
Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, *ERK* and c-Src/FAK associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.

HY-W008947

SEW2871	LPL Receptor ERK Akt	Metabolic Disease Inflammation/Immunology Neurological Disease
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates *ERK, Akt, and Rac* signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses.

HY-119016

SK1-I BML-258	SphK	Cancer
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of 10 µM. SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity.

HY-142283

Dosimertinib	EGFR	Cancer
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-10182B

Laduviglusib trihydrochloride CHIR-99021 trihydrochloride; CT99021 trihydrochloride	GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy.

HY-146537

KRAS G12C inhibitor 47	Ras	Cancer
KRAS G12C inhibitor 47 (compound 8-1-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.172 µM. KRAS G12C inhibitor 47 shows p-ERK inhibition activities with IC₅₀s of 0.046, 69.8 µM in MIA PaCA-2, A549 cells, respectively. KRAS G12C inhibitor 47 has the potential for the research of pancreatic, colorectal, and lung cancers.

HY-10182

Laduviglusib CHIR-99021; CT99021	GSK-3 Wnt β-catenin Autophagy	Cancer Metabolic Disease
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.

HY-108635

C16-PAF PAF (C16)	p38 MAPK MEK ERK Endogenous Metabolite	Inflammation/Immunology Cardiovascular Disease
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and *MEK/ERK* activator. C16-PAF induces increased vascular permeability.

HY-P4322

H-Ile-Lys-Val-Ala-Val-OH	ERK Akt	Cancer Neurological Disease
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating *MAPK/ERK1/2* and PI3K/Akt signalling pathways.

HY-N3807

Enniatin B1	Acyltransferase ERK NF-κB	Cancer Infection Cardiovascular Disease
Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier. Enniatin B1 decreases the activation of *ERK* (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation.

HY-N10802

6-O-Isobutyrylbritannilactone	ERK Akt PI3K Epigenetic Reader Domain	Cancer
6-O-Isobutyrylbritannilactone is a natural melanogenesis inhibitor. 6-O-Isobutyrylbritannilactone, a sesquiterpene, can be isolated from the flowers of Inula britannica. 6-O-Isobutyrylbritannilactone inhibits IBMX (HY-12318)-induced melanin production in B16F10 cells. 6-O-Isobutyrylbritannilactone also regulates *ERK, PI3K/AKT, and CREB*, shows antimelanogenic activity in zebrafish embryos models.

HY-17437

Mefloquine Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Cancer Infection Metabolic Disease Inflammation/Immunology
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research.

HY-123942

Diprovocim	Toll-like Receptor (TLR) TNF Receptor p38 MAPK NF-κB	Cancer Inflammation/Immunology
Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses.

HY-152079

CYP1B1-IN-3	Cytochrome P450	Cancer
CYP1B1-IN-3 is a potent and selective CYP1B1 inhibitor with IC₅₀ values of 6.6, 347.3, >10000 nM for CYP1B1, CYP1A1, CYP1A2, respectively. CYP1B1-IN-3 inhibits cell migration and invasion. CYP1B1-IN-3 inhibits P-gp, AKT/ERK, FAK/SRC, and EMT pathways.

HY-10182A

Laduviglusib monohydrochloride CHIR-99021 monohydrochloride; CT99021 monohydrochloride	GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy.

HY-12843

Bohemine	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits *ERK2* with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities.

HY-N6257

Cafestol	ERK PGE synthase COX NF-κB	Cancer Inflammation/Immunology
Cafestol, one of the major components of coffee, is a coffee-specific diterpene from. Cafestol is a *ERK* inhibitor for AP-1-targeted activity against PGE₂ production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells. Cafestol has strong inhibitory activity on PGE₂ production by suppressing the NF-kB activation pathway. Cafestol contributes to its beneficial effects through various biological activities such as chemopreventive, antitumorigenic, hepatoprotective, antioxidative and antiinflammatory effects.

HY-150026

Multi-kinase-IN-2	VEGFR PDGFR FGFR c-Kit Akt Src Apoptosis	Cancer
Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and *ERK* proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity.

HY-N0619A

cis-Mulberroside A Mulberroside D	TNF Receptor Interleukin Related Tyrosinase	Inflammation/Immunology
cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory and anti-apoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM.

HY-117720

OSU-2S	PKC Apoptosis	Cancer
OSU-2S is a potent PKCδ activator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib (HY-10201). OSU-2S induces Apoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity.

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells.

HY-150795

SY-LB-35	TGF-beta/Smad PI3K Akt ERK JNK	Others
SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt, *ERK, p38* and JNK intracellular signaling pathways.

HY-148098

Pan KRas-IN-1
Ras Cancer

Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors.

HY-P1844A

Chemerin-9 (149-157) (TFA)	Akt ERK Reactive Oxygen Species Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism.

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Metabolic Disease Cardiovascular Disease
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-B0660

Eicosapentaenoic Acid EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-N2038

3,5,6,7,8,3',4'-Heptemthoxyflavone	Phosphodiesterase (PDE)	Cancer Neurological Disease
3,5,6,7,8,3',4'-heptamethoxyflavone, a flavonoid in Citrus reticulata peels, exhibits anti-tumor-initiating effect and Anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-heptamethoxyflavone inhibits collagenase activity and increased type I procollagen content in HDFn cells. 3,5,6,7,8,3',4'-heptamethoxyflavone induces brain-derived neurotrophic factor (BDNF) expression via cAMP/ERK/CREB signaling and reduces phosphodiesterase activity in C6 cells.

HY-12624

Narazaciclib ON123300	CDK AMPK PDGFR	Cancer
Narazaciclib (ON123300), a strong and brain-penetrant multi-kinase inhibitor, inhibits CDK4 (IC₅₀=3.9 nM), Ark5 (IC₅₀=5 nM), PDGFRβ (IC₅₀=26 nM), FGFR1 (IC₅₀=26 nM), RET (IC₅₀=9.2 nM), and FYN (IC₅₀=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors. Narazaciclib inhibits CDK6 with an IC₅₀ of 9.82 nM.

HY-P2265

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.

HY-112457

MK2-IN-3 hydrate	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC₅₀ of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC₅₀=0.21 μM), MK-5 (IC₅₀=0.081 μM), ERK2 (IC₅₀=3.44 μM), MNK1(IC₅₀=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2.

HY-109041

Razuprotafib AKB-9778	Phosphatase	Inflammation/Immunology
Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM).

HY-N10009

Cudraflavone B	NF-κB TNF Receptor COX ERK p38 MAPK Sirtuin	Inflammation/Immunology
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and *ERK, and induced the expression of SIRT1*. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells.

HY-124858

SC99	STAT JAK Apoptosis	Cancer Cardiovascular Disease
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities.

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research.

HY-P2265A

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.

HY-131249

MK2-IN-3	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC₅₀ of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC₅₀s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC₅₀s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo.

HY-149824

EGFR T790M/L858R-IN-2	EGFR Apoptosis	Cancer
EGFRT790M/L858R-IN-2 is a potent and selective EGFRT790M/L858R inhibitor with IC₅₀ values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. EGFRT790M/L858R-IN-2 decreases the expression of p-EGFR, P-AKT, P-ERK1/2. EGFRT790M/L858R-IN-2 induces Apoptosis and cell cycle arrest in the G1 phase. EGFRT790M/L858R-IN-2 shows anti-cancer activity.

HY-106381

Aurothiomalate sodium	PKC	Cancer Inflammation/Immunology
Aurothiomalate sodium is a potent and selective oncogenic PKC_ι signaling inhibitor. Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium, an anti-rheumatoid agent, exhibits potent anti-tumor activity.

Cat. No.	Product Name

HY-L010

MAPK Compound Library

347 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 347 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

HY-L139

Pain-Related Compound Library

1627 compounds

Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot.

MCE supplies a unique collection of 1627 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

HY-L101

Anti-Liver Cancer Compound Library

1596 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 1596 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

HY-L045

Oxygen Sensing Compound Library

2051 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 2051 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF. Storage: protect from light.

Cat. No.	Product Name	Target	Research Area

HY-P3751

[Tyr8] Bradykinin	Bradykinin Receptor ERK	Endocrinology Cardiovascular Disease
[Tyr8] Bradykinin is a B₂ kinin receptor agonist. [Tyr8] Bradykinin also stimulates ERK1/2 phosphorylation. [Tyr8] Bradykinin can be used as an internal standard.

HY-P4497

Prolylserine	ERK Peptides	Cancer
Prolylserine, a dipeptide, is an inhibitor of melanogenesis production in Mel-Ab cells. Prolylserine decreases expression of microphthalmia-associated transcription factor (MITF) and tyrosinase, induces phorphosylation of *ERK, but not cAMP response element binding protein (CREB)*.

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research.

HY-P1844

Chemerin-9 (149-157)	Akt ERK Reactive Oxygen Species Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism.

HY-P3992

5-FAM-Dyrktide
Peptides Others

5-FAM-Dyrktide is a 5-FAM labeled Dyrktide. Dyrktide, a substrate, is efficiently phosphorylated by DYRK1A (K_m=35 μM) but not by ERK2.

HY-P3513

β-Neo-Endorphin	ERK MMP	Neurological Disease
β-Neo-Endorphin is an endogenous opioid peptide. β-Neo-Endorphin is a hypothalamic “big” Leu-enkephalin of porcine origin. β-Neo-Endorphin shows activation of the *Erk1/2, MMP-2* and MMP-9.

HY-P1342

Prosaptide Tx14(A)	Peptides	Neurological Disease
Prosaptide Tx14(A), a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) increases both ERK1 and ERK2 phosphorylation in Schwann cells.

HY-P1342A

Prosaptide Tx14(A) TFA	Peptides	Neurological Disease
Prosaptide Tx14(A) TFA, a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) TFA increases both ERK1 and ERK2 phosphorylation in Schwann cells.

HY-110366

WAY-181187 oxalate SAX-187 oxalate	5-HT Receptor	Neurological Disease
WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a K_i of 2.2 nM and an EC₅₀ of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-P4159

Endothelin-1 (1-31) (Human)	ERK	Cardiovascular Disease
Endothelin-1 (1-31) (Human) is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) is derived from the selective hydrolysis of big ET-1 by chymase.

HY-P3750

Methionyl-Lysyl-Bradykinin Met-Lys-Bradykinin	Bradykinin Receptor	Endocrinology Cardiovascular Disease
Methionyl-Lysyl-Bradykinin (Met-Lys-Bradykinin), a Bradykinin (HY-P0206) analogue, is a kinin.

HY-P4159B

Endothelin-1 (1-31) (Human) acetate	ERK	Cardiovascular Disease
Endothelin-1 (1-31) (Human) acetate is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) acetate is derived from the selective hydrolysis of big ET-1 by chymase.

HY-P4159A

Endothelin-1 (1-31) (Human) TFA	ERK	Cardiovascular Disease
Endothelin-1 (1-31) (Human) TFA is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) TFA is derived from the selective hydrolysis of big ET-1 by chymase.

HY-P3418A

CKLF1-C27 TFA	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates *ERK1/2* pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research.

HY-P3418

CKLF1-C27	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates *ERK1/2* pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research.

HY-P4136

Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits *ERK* activation with an IC₅₀ of 10 μM.

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of *ERK2* by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable.

HY-149205

CXJ-2	PI3K ERK	Inflammation/Immunology
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the *PI3K/ERK* pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy.

HY-P4052

Pinealon	ROS Kinase	Neurological Disease
Pinealon is a 3-amino acid peptide and shows neuroprotective properties. Pinealon prevents reactive oxygenspecies (ROS) accumulation and supressesthe activation of ERK 1/2. Pinealon has the ability to stimulate the functional activity of the main cellular elements of brain tissue, reduce the level of spontaneous cell death. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.

HY-P4322

H-Ile-Lys-Val-Ala-Val-OH	ERK Akt	Cancer Neurological Disease
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating *MAPK/ERK1/2* and PI3K/Akt signalling pathways.

HY-P2262

TAT-DEF-Elk-1 TDE	Peptides	Neurological Disease
TAT-DEF-Elk-1 (TDE) is a cell-penetrating peptide inhibitor of Elk-1, mimics and specifically interferes with the DEF domain of Elk-1. TAT-DEF-Elk-1 blocks Elk-1 phosphorylation and prevents Elk-1 nuclear translocation without interfering with ERK nor MSK1 activation. TAT-DEF-Elk-1 is a useful tool to analyze the role of Elk-1 in this process during the development of neuronal plasticity.

HY-P2262A

TAT-DEF-Elk-1 TFA TDE TFA	Peptides	Neurological Disease
TAT-DEF-Elk-1 TFA (TDE TFA) is a cell-penetrating peptide inhibitor of Elk-1, mimics and specifically interferes with the DEF domain of Elk-1. TAT-DEF-Elk-1 TFA blocks Elk-1 phosphorylation and prevents Elk-1 nuclear translocation without interfering with ERK nor MSK1 activation. TAT-DEF-Elk-1 TFA is a useful tool to analyze the role of Elk-1 in this process during the development of neuronal plasticity.

HY-P1844A

Chemerin-9 (149-157) (TFA)	Akt ERK Reactive Oxygen Species Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism.

HY-P2265

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research.

HY-P2265A

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.

Cat. No.	Product Name	Target	Research Area

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and *ERK*. Abituzumab can be used in cancer research, particularly in prostate cancer.

HY-P99275

Patritumab Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, *ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

Cat. No.	Product Name	Target	Category

HY-N6076

Tenuifoliside A	ERK	Terpenoids Triterpenes Phenols Monophenols Source classification Plants Polygalaceae Polygala tenuifolia Willd.
Tenuifoliside A is isolated from Polygala tenuifolia, has anti-apoptotic and antidepressant-like effects. Tenuifoliside A exhibits its neneurotrophic effects and promotes cell proliferation through the *ERK/CREB/BDNF* signal pathway in C6 cells.

HY-N3711

Dehydrocrenatine	JNK ERK Apoptosis	Indole Alkaloids Source classification Plants Simaroubaceae Picrasma chinensis P. Y. Chen
Dehydrocrenatidine, a β-carboline alkaloid that can be isolated from Picrasma quassioides. Dehydrocrenatidine induces cell apoptosis by activates *ERK* and JNK. Dehydrocrenatidine inhibits invasion and migration of cancer cells, it also suppresses neuronal excitability to exert analgesic effects.

HY-N8211

Gypenoside L	p38 MAPK ERK NF-κB	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Cucurbitaceae Gynostemma pentaphyllum (Thunb.) Makino
Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines. Gypenoside L also can activate p38 and ERK MAPK pathways and NF-κB pathway to induce senescence. Gypenoside L exhibits anti-tumor and anti-inflammatory activities.

HY-134000

Emodic acid NSC624610	p38 MAPK NF-κB ERK JNK VEGFR MMP	Quinones Anthraquinones Structural Classification Leguminosae Plants Source classification Cercis chinensis Bunge
Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, *ERK* and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP, thereby inhibiting the invasion and migration potential of cancer cells.

HY-N1381

Periplocin	Apoptosis	Steroids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Asclepiadaceae Periploca sepium Bunge
Periplocin is a cardiotonic steroid isolated from root-bark Periploca sepium Bunge. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase.

HY-N0590

Corynoxeine	ERK	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Plants Rubiaceae Uncaria rhynchophylla (Miq.) Miq. ex Havil.
Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent *ERK1/ERK2* inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.

HY-16558

Butein 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Chalcones Phenols Polyphenols Structural Classification Flavonoids other families Plants Source classification Disease Research Fields Cancer Anti-aging Classification of Application Fields
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60^c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).

HY-N8418

Cearoin	Autophagy Reactive Oxygen Species ERK Apoptosis	Ketones, Aldehydes, Acids Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Leguminosae Dalbergia odorifera T. Chen
Cearoin increases autophagy and apoptosis through the production of ROS and the activation of *ERK*.

HY-N1374

Magnolin	ERK	Phenylpropanoids Lignans Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Magnoliaceae Magnolia Liliflora Desr.
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of *ERK1* and *ERK2* with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-N2283

Deltonin	ERK Akt Endogenous Metabolite	Steroids Structural Classification Dioscoreaceae Dioscorea Zingiberensis C.H.Wright Endogenous metabolite Plants Source classification Disease Research Fields Cancer Classification of Application Fields
Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis, with antitumor activity; Deltonin inhibits *ERK1/2* and AKT activation.

HY-N2312

Mogrol	ERK STAT	Triterpenes Structural Classification Terpenoids Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Cucurbitaceae Disease Research Fields Cancer Classification of Application Fields
Mogrol is a biometabolite of mogrosides, and acts via inhibition of the *ERK1/2* and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Phenols Monophenols Antibiotics Macrolide Antibiotics Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and *ERK1/ERK2*, respectively.

HY-N1507

Tracheloside	Estrogen Receptor/ERR	Phenylpropanoids Structural Classification Lignans other families Plants Source classification Disease Research Fields Cancer Classification of Application Fields
Tracheloside is an antiestrogenic lignin. Tracheloside promotes keratinocyte proliferation through ERK1/2 stimulation. Tracheloside is a good candidate to promote wound healing.

HY-W001174

2,5-Dihydroxyacetophenone	ERK NF-κB	Phenols Polyphenols Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Scrophulariaceae Rehmannia glutinosa (Gaert.) Libosch. ex Fisch. et Mey
2,5-Dihydroxyacetophenone, isolated from Rehmannia glutinosa, inhibits the production of inflammatory mediators in activated macrophages by blocking the *ERK1/2* and NF-κB signaling pathways.

HY-N3828

epi-Eriocalyxin A	Apoptosis ERK JNK	Terpenoids Other Terpenoids Source classification Plants
epi-Eriocalyxin A (Epieriocalyxin A), a diterpenoid isolated from Isodon eriocalyx, induces colon cancer apoptosis. epi-Eriocalyxin A also inhibits *ERK1/2* and JNK activation, which suppresses Bcl-2 expression.

HY-N0431

Astragaloside IV	MMP ERK JNK	Triterpenes Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Leguminosae Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of *ERK1/2* and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

HY-N6007

Chrysosplenol D	Apoptosis	Flavonoids Flavonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Infection Inflammation/Immunology Source classification Plants other families
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities.

HY-N6577

Astragaloside VI	EGFR	Terpenoids Triterpenes Source classification Plants Leguminosae Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao other families
Astragaloside VI could activate *EGFR/ERK* signalling pathway to improve wound healing.

HY-N10175

Berkeleyacetal C	Fungal Endogenous Metabolite	Terpenoids Other Terpenoids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Microorganisms
Berkeleyacetal C, a meroterpenoid compound, shows favorable activity of inhibiting nitrogen oxide (NO) production of macrophages stimulated by lipopolysaccharide (LPS). Berkeleyacetal C exerts anti-inflammatory effects via inhibiting NF-κB, ERK1/2 and IRF3 signaling pathways.

HY-129566

Withanolide B	ERK Wnt β-catenin	Steroids Classification of Application Fields Disease Research Fields Inflammation/Immunology Metabolic Disease Neurological Disease Source classification Plants Solanaceae Withania somnifera
Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via *ERK1/2* and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.

HY-N0371

Pachymic acid 3-O-Acetyltumulosic acid	Akt ERK	Triterpenes Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Polyporaceae Poria cocos
Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and *ERK* signaling pathways.

HY-N10047

7,8-Didehydrocimigenol	NF-κB PPAR	Triterpenes Terpenoids Structural Classification Ranunculaceae Cimicifuga foetida Linn. Plants Source classification
7,8-Didehydrocimigenol is an active triterpenoid that can be isolated from Cimicifugae rhizoma. 7,8-Didehydrocimigenol inhibits TNF-α-induced VCAM-1 expression, inhibits NF-kB activity and phosphorylation of ERK1/2 and Akt, increases PPAR-γ expression. 7,8-Didehydrocimigenol can be used for the research of cardiovascular disorders such as atherosclerosis.

HY-N1987

Cucurbitacin IIb	Apoptosis	Triterpenes Terpenoids Inflammation/Immunology Disease Research Fields Classification of Application Fields Plants Cucurbitaceae Hemsleya amabilis Diels
Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α.

HY-122404

Xantocillin Xanthocillin X	MEK ERK Autophagy	Phenols Polyphenols Structural Classification Marine microorganism Microorganisms Marine natural products Source classification Disease Research Fields Cancer Classification of Application Fields
Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the *MEK/ERK* pathway.

HY-N2329

Piperlongumine Piplartine	ERK Reactive Oxygen Species Autophagy Apoptosis Bacterial Ferroptosis	Alkaloids Pyridine Alkaloids Infection Disease Research Fields Classification of Application Fields Cardiovascular Disease Source classification Plants Piperaceae Piper longum Linn.
Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome.

HY-N0774

Isofraxidin	COX MMP Toll-like Receptor (TLR)	Coumarins Phenylpropanoids Monophenols Phenols Structural Classification Araliaceae Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits MMP-7 expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of *ERK1/2* in hepatoma cells. Isofraxidin attenuates the expression of iNOS and COX-2, Isofraxidinalso inhibits TLR4/myeloid differentiation protein-2 (MD-2) complex formation.

HY-N1818

Deoxysappanone B 3-Deoxysappanone B	p38 MAPK	Structural Classification Phenols Polyphenols Source classification Plants Leguminosae Caesalpinia sappan L.
Deoxysappanone B (3-Deoxysappanone B) is a homoisoflavone compound isolated from Caesalpinia sappan L (Lignum Sappan). Deoxysappanone B has anti-neuroinflammatory and neuroprotective effects and inhibits the production of neuroinflammatory mediators by blocking the IκB kinase (IKK)-NF-κB and p38/ERK MAPK pathways. Deoxysappanone B can be used in disease studies of neuritis and inflammation-related neurological damage.

HY-N0265

Asperosaponin VI	Caspase Apoptosis	Triterpenes Terpenoids Disease Research Fields Classification of Application Fields Cardiovascular Disease Source classification Plants Dipsacaceae Dipsacus asper
Asperosaponin VI, A saponin component from Dipsacus asper, induces osteoblast differentiation through BMP‐2/p38 and ERK1/2 pathway. Asperosaponin Ⅵ inhibits apoptosis in hypoxia-induced cardiomyocyte by increasing the Bcl-2/Bax ratio and decreasing active caspase-3 expression, as well as enhancing of p-Akt and p-CREB.

HY-19700

trans-Zeatin	MEK ERK Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Other Diseases Source classification Plants Gramineae Zea mays L. Endogenous metabolite
trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced *MEK/ERK* activation.

HY-N11439

Albanol B	CDK Akt ERK Apoptosis Bacterial	Structural Classification Phenols Polyphenols Natural Products Morus alba L. Plants Source classification Moraceae
Albanol B is an arylbenzofuran derivative which can be isolated from mulberries. Albanol B exhibits anti-Alzheimer's disease, anti-bacterial and antioxidant activities. Albanol B inhibits cancer cells proliferation, down-regulates CDK1 expression. Albanol B also induces cell cycle arrest at G2/M and apoptosis. And Albanol B induces mitochondrial ROS production and increases the phosphorylation levels of AKT and *ERK1/2*.

HY-19696

Tauroursodeoxycholate Tauroursodeoxycholic acid; TUDCA; UR 906	ERK Caspase Endogenous Metabolite Apoptosis	Steroids Disease Research Fields Cancer Classification of Application Fields Source classification Endogenous metabolite
Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits *ERK*.

HY-N2484

Methylnissolin Astrapterocarpan	PDGFR ERK	Other Flavonoids Monophenols Phenols Flavonoids Disease Research Fields Classification of Application Fields Cardiovascular Disease Source classification Plants Leguminosae Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC₅₀ of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the *ERK1/2* MAP kinase cascade.

HY-113509

Lipoxin A4 LXA4	Interleukin Related Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Endogenous metabolite
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC₅₀ value of 25.74 nM.

HY-N1966

(E)-Osmundacetone	p38 MAPK JNK ERK	Phenols Polyphenols Source classification Microorganisms
(E)-Osmundacetone is the isomer of Osmundacetone. Osmundacetone significantly suppresses the phosphorylation of MAPKs, including JNK, ERK, and p38 kinases. Osmundacetone has a neuroprotective effect against oxidative stress.

HY-N2270

Chicanine	p38 MAPK ERK IKK	Phenylpropanoids Monophenols Phenols Lignans Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.
Chicanine is a lignan compound of Schisandra chinesis, inhibits LPS-induced phosphorylation of p38 MAPK, ERK 1/2 and IκB-α, with anti-inflammatory activity.

HY-N6264

26-Deoxyactein	Aryl Hydrocarbon Receptor ERK	Triterpenes Terpenoids Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Ranunculaceae Cimicifuga foetida Linn. Cimicifuga racemosa
26-Deoxyactein is a constituent isolated from Cimicifuga racemosa, prevents TCDD-induced osteoblasts damage. 26-Deoxyactein inhibits increased AhR, CYP1A1 and ERK levels.

HY-N2051

Zeylenone	Apoptosis	Natural Products Classification of Application Fields Disease Research Fields Cancer Source classification Plants Annonaceae Uvaria grandiflora Roxb.
Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.

HY-N6826

Asatone	NF-κB	Natural Products Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Aristolochiaceae Asarum sieboldii Miq.
Asatone is an active component isolated from Radix et Rhizoma Asari, with anti-inflammatory effect via activation of NF-κB and donwn regulation of p-MAPK (ERK, JNK and p38) pathways.

HY-113599

Isoprocurcumenol	EGFR ERK Akt	Sesquiterpenes Structural Classification Terpenoids Source classification Plants Zingiberaceae Curcuma comosa Roxb.
Isoprocurcumenol is a guaiane type sesquiterpene, that can be isolated from Curcuma comosa. Isoprocurcumenol can activate EGFR signaling. Isoprocurcumenol increases the phosphorylation of *ERK* and AKT. Isoprocurcumenol promotes the proliferation of keratinocytes.

HY-N1504

Loureirin B	PAI-1 Potassium Channel ERK JNK	Flavonoids Dihydrochalcones Phenols Monophenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Agavaceae Dracaena cochinchinensis (Lour.) S. C. Chen
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of *ERK* and JNK, and has anti-diabetic activity.

HY-N7108

7-Hydroxyflavone	ERK Keap1-Nrf2	Structural Classification Flavones Flavonoids Clerodendrum phlomidis Verbenaceae Plants Inflammation/Immunology Disease Research Fields Classification of Application Fields
7-Hydroxyflavone is a flavonoid isolated from Clerodendrum phlomidis, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway.

HY-N2375

L-Quebrachitol	Wnt β-catenin	Natural Products Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants other families
L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway.

HY-N0226

Epiberberine	Cholinesterase (ChE) Beta-secretase	Isoquinoline Alkaloids Alkaloids Source classification Plants Ranunculaceae Coptis chinensis Franch.
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Epiberberinecan be used for the research of diabetic disease.

HY-N0226A

Epiberberine chloride	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species	Isoquinoline Alkaloids Alkaloids Neurological Disease Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Ranunculaceae Coptis chinensis Franch.
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease. Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Epiberberine has the potential effect in the research of diabetic disease.

HY-N8303

Gardenin A	ERK PAK	Structural Classification Flavones Flavonoids Source classification Plants Rutaceae Citrus reticulata Blanco
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating *MAPK/ERK, PKC, and PKA*, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects.

HY-N3806

Enniatin B	Acyltransferase ERK	Alkaloids Other Alkaloids Infection Disease Research Fields Classification of Application Fields Cardiovascular Disease Source classification Microorganisms
Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of *ERK* (p44/p42).

HY-N0809

Sesamolin	p38 MAPK JNK Caspase	Other Phenylpropanoids Phenylpropanoids Source classification Plants Pedaliaceae Sesamum indicum Linn.
Sesaminol, isolated from Sesamum indicum, has antioxidative activity, Sesaminol inhibits lipid peroxidation and shows neuroprotection effect. Sesaminol potently inhibits MAPK cascades by preventing phosphorylation of JNK, p38 MAPKs, and caspase-3 but not ERK-MAPK expression.

HY-32736

Triptonide NSC 165677; PG 492	Wnt β-catenin Apoptosis Autophagy	Terpenoids Diterpenoids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Celastraceae Tripterygium wilfordii Hook. f.
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC₅₀ of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.

HY-N0745

Senkyunolide I	Caspase	Natural Products Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Umbelliferae Ligusticum chuanxiong Hort.
Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.

HY-N2450

Sulforaphene	Apoptosis EGFR ERK NF-κB	Natural Products Disease Research Fields Cancer Classification of Application Fields Source classification Plants Brassicaceae Raphanus sativus Linn.
Sulforaphene, isolated from radish seeds, exhibits an ED₅₀ against velvetleaf seedlings approximately 2 x 10^-4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, *p-ERK1/2, NF‐κB* and other signals.

HY-N2208

4-Hydroxylonchocarpin	p38 MAPK	Flavonoids Chalcones Phenols Polyphenols Classification of Application Fields Disease Research Fields Infection Inflammation/Immunology Metabolic Disease Source classification Plants Leguminosae Psoralea corylifolia L.
4-Hydroxylonchocarpin is a chalcone compound from an extract of Psoralea corylifolia. 4-Hydroxylonchocarpin increases phosphorylation of p38 MAPK, JNK and ERK. 4-Hydroxylonchocarpin has diverse pharmacological activities, including antibacterial, antifungal, anticancer, antireverse transcriptase, antitubercular, antimalarial, anti-inflammatory and antioxidant activities.

HY-126307

Urolithin B	NF-κB JNK ERK Akt AMPK Endogenous Metabolite	Phenols Monophenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Endogenous metabolite
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, *ERK, and Akt, and enhances the phosphorylation of AMPK*. Urolithin B is also a regulator of skeletal muscle mass.

HY-N2963

Broussonin E	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase	Structural Classification Phenols Polyphenols Source classification Plants Thymelaeaceae Daphne giraldii Nitsche
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the *ERK* and p38 MAPK and enhancing JAK2-STAT3 signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis.

HY-N4042

Hirsutenone	PI3K ERK	Phenols Polyphenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Betulaceae Alnus cremastogyne Burk.
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and *ERK1* in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity.

HY-N3071

Picrasidine I	Apoptosis Reactive Oxygen Species	Indole Alkaloids Source classification Plants Simaroubaceae Quassia amaraL.
Picrasidine I is an anti-inflammatory and anti-osteoclastogenic dimeric alkaloid that can be isolated from Picrasma quassioides. Picrasidine I inducs cell cycle arrest, and triggers cell apoptosis by downregulats *ERK* and Akt pathways. Picrasidine I inhibits the activation of MAPKs, NF-κB and ROS generation, and suppresses the expression of c-Fos and NFATc1.

HY-N3298

Meranzin	Adrenergic Receptor	Phenylpropanoids Coumarins Classification of Application Fields Disease Research Fields Cardiovascular Disease Neurological Disease Source classification Plants other families
Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway. Meranzin has the potential for the prevention of the comorbidity of atherosclerosis and depression.

HY-N6704

Enniatin A1	ERK Apoptosis	Antibiotics Macrolide Antibiotics Disease Research Fields Cancer Classification of Application Fields Source classification Microorganisms
Enniatin A1 isolated from Fusarium mycotoxins is a cyclic hexadepsipeptide consisting of alternating D-α-hydroxyisovaleric acids and N-methyl-L-amino acids. Enniatin A1 possesses anticarcinogenic properties by induction of apoptosis and disruption of *ERK* signalling pathway. Enniatin A1 inhibits ACAT with an IC₅₀ of 49 μM in rat liver microsomes.

HY-N0104

Curcumol (-)-Curcumol	Apoptosis	Terpenoids Sesquiterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants Zingiberaceae Curcuma zedoaria
Curcumol ((-)-Curcumol), a bioactive sesquiterpenoid, possesses numerous pharmacological activities like anticancer, antimicrobial, antifungal, antiviral, and antiinflammatory. Curcumol is a potent inducer of apoptosis in numerous cancer cells via targeting key signaling pathways as MAPK/ERK, PI3K/Akt and NF-κB which are generally deregulated in several cancers.

HY-N7110

6-Hydroxyflavone	Akt ERK JNK	Monophenols Phenols Flavones Structural Classification Flavonoids Labiatae Scutellaria baicalensis Georgi Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
6-Hydroxyflavone is a naturally occurring flavone, with anti-inflammatory activity. 6-Hydroxyflavone exhibits inhibitory effect towards bovine hemoglobin (BHb) glycation. 6-Hydroxyflavone can activate AKT, ERK 1/2, and JNK signaling pathways to effectively promote osteoblastic differentiation. 6-Hydroxyflavone inhibits the LPS-induced NO production .

HY-N1930

(-)-Hinesol Hinesol	Apoptosis	Natural Products Plants Compositae Erythrina sigmoidea Hua
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer.

HY-N0678

Icaritin Anhydroicaritin	Autophagy Apoptosis	Flavonols Phenols Polyphenols Structural Classification Flavonoids Epimedium brevicornu Maxim. Plants Berberidaceae Source classification Disease Research Fields Cancer Classification of Application Fields
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate *MAPK/ERK/JNK* and JAK2/STAT3 /AKT signalings, also enhances osteogenesis^[3.

HY-N0619

Mulberroside A	TNF Receptor Interleukin Related Tyrosinase	Phenols Stilbenes Polyphenols Structural Classification Morus alba L. Plants Source classification Moraceae Inflammation/Immunology Disease Research Fields Classification of Application Fields
Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM.

HY-N6796

Manumycin A	Farnesyl Transferase Ras Apoptosis Phospholipase	Antibiotics Other Antibiotics Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling. Manumycin A is a nSMase inhibitor (EC₅₀=0.25 μM).

HY-N0498

Nitidine chloride	Parasite Apoptosis STAT Topoisomerase ERK FAK p38 MAPK NF-κB	Isoquinoline Alkaloids Alkaloids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Rutaceae Zanthoxylum nitidum (Roxb.) DC.
Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, *ERK* and c-Src/FAK associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.

HY-N3807

Enniatin B1	Acyltransferase ERK NF-κB	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Infection Source classification Microorganisms
Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier. Enniatin B1 decreases the activation of *ERK* (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation.

HY-N10802

6-O-Isobutyrylbritannilactone	ERK Akt PI3K Epigenetic Reader Domain	Structural Classification Terpenoids Compositae Orchidaceae Helianthus tuberosus L. Plants Source classification
6-O-Isobutyrylbritannilactone is a natural melanogenesis inhibitor. 6-O-Isobutyrylbritannilactone, a sesquiterpene, can be isolated from the flowers of Inula britannica. 6-O-Isobutyrylbritannilactone inhibits IBMX (HY-12318)-induced melanin production in B16F10 cells. 6-O-Isobutyrylbritannilactone also regulates *ERK, PI3K/AKT, and CREB*, shows antimelanogenic activity in zebrafish embryos models.

HY-N6257

Cafestol	ERK PGE synthase COX NF-κB	Terpenoids Diterpenoids Inflammation/Immunology Disease Research Fields Cancer Classification of Application Fields Plants Rubiaceae
Cafestol, one of the major components of coffee, is a coffee-specific diterpene from. Cafestol is a *ERK* inhibitor for AP-1-targeted activity against PGE₂ production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells. Cafestol has strong inhibitory activity on PGE₂ production by suppressing the NF-kB activation pathway. Cafestol contributes to its beneficial effects through various biological activities such as chemopreventive, antitumorigenic, hepatoprotective, antioxidative and antiinflammatory effects.

HY-N0619A

cis-Mulberroside A Mulberroside D	TNF Receptor Interleukin Related Tyrosinase	Phenols Stilbenes Polyphenols Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Moraceae Morus alba Linn.
cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory and anti-apoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM.

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Endogenous metabolite
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-B0660

Eicosapentaenoic Acid EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Neurological Disease Source classification Endogenous metabolite
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-N2038

3,5,6,7,8,3',4'-Heptemthoxyflavone	Phosphodiesterase (PDE)	Structural Classification Flavonols Flavonoids Rutaceae Citrus reticulata Blanco Plants
3,5,6,7,8,3',4'-heptamethoxyflavone, a flavonoid in Citrus reticulata peels, exhibits anti-tumor-initiating effect and Anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-heptamethoxyflavone inhibits collagenase activity and increased type I procollagen content in HDFn cells. 3,5,6,7,8,3',4'-heptamethoxyflavone induces brain-derived neurotrophic factor (BDNF) expression via cAMP/ERK/CREB signaling and reduces phosphodiesterase activity in C6 cells.

HY-N10009

Cudraflavone B	NF-κB TNF Receptor COX ERK p38 MAPK Sirtuin	Structural Classification Phenols Polyphenols Brosimopsis oblongifolia Plants Source classification Moraceae
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and *ERK, and induced the expression of SIRT1*. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells.

Species:	Human (9) Mouse (6) Cynomolgus (1)
Tag:	His (11) Tag Free (3) GST (5) Fc (2)
Source:	HEK293 (7) Sf9 insect cells (7) P. pastoris (1) E. coli (1)

Cat. No.	Product Name	Species	Source

HY-P77647

EphB2 Protein, Mouse (525a.a, HEK293, His)
DRT; ERK; HEK5; TYRO5; CAPB; EK5; EPHT3; PCBC; Cek5; EphB2; EPHT3MGC87492; Nuk; Qek2; Sek3
Mouse HEK293
HY-P700716

EphB2 Protein, Cynomolgus (HEK293, His)
DRT; ERK; HEK5; TYRO5; CAPB; EK5; EPHT3; PCBC; Cek5; EphB2; EPHT3MGC87492; Nuk; Qek2; Sek3
Cynomolgus HEK293
HY-P73001

EphB2 Protein, Human (HEK293, His-Fc)
EPHB2; Ephrin type-B receptor 2; EK5; DRT; EPHT3; ERK; HEK5; TYRO5
Human HEK293
HY-P73000

EphB2 Protein, Human (sf9, His-GST)
EPHB2; Ephrin type-B receptor 2; EK5; DRT; EPHT3; ERK; HEK5; TYRO5
Human Sf9 insect cells
HY-P72999

EphB2 Protein, Human (HEK293)
EPHB2; Ephrin type-B receptor 2; EK5; DRT; EPHT3; ERK; HEK5; TYRO5
Human HEK293
HY-P75237

EphB2 Protein, Human (HEK293, His)
EPHB2; Ephrin type-B receptor 2; EK5; DRT; EPHT3; ERK; HEK5; TYRO5
Human HEK293
HY-P75236

EphB2 Protein, Mouse (HEK293, Fc)
EPHB2; Ephrin type-B receptor 2; EK5; DRT; EPHT3; ERK; HEK5; TYRO5
Mouse HEK293
HY-P75235

EphB2 Protein, Mouse (HEK293, His)
EPHB2; Ephrin type-B receptor 2; EK5; DRT; EPHT3; ERK; HEK5; TYRO5
Mouse HEK293
HY-P75223

ERK2 Protein, Human (sf9, GST)
Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK
Human Sf9 insect cells
HY-P74168

ERK2 Protein, Mouse (sf9)
Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK
Mouse Sf9 insect cells
HY-P74167

ERK2 Protein, Mouse (sf9, His-GST)
Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK
Mouse Sf9 insect cells
HY-P76532

p38 gamma/MAPK12 Protein, Human (sf9)
Mitogen-activated protein kinase 12; Extracellular signal-regulated kinase 6; ERK-6; SAPK3
Human Sf9 insect cells
HY-P76533

p38 gamma/MAPK12 Protein, Human (sf9, His-GST)
Mitogen-activated protein kinase 12; Extracellular signal-regulated kinase 6; ERK-6; SAPK3
Human Sf9 insect cells

HY-P700593

MAP3K1 Protein, Mouse (His) MEKK; MEKK1; SRXY6; MEKK 1; MAPKKK1; MAP/ERK kinase kinase 1; MAPK/ERK kinase kinase 1; MEK kinase 1; mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase; mitogen-activated protein kinase kinase kinase 1	Mouse	E. coli

HY-P700589

MAP2K4 Protein, Human (P. pastoris, His-GST) MAP2K4; mitogen-activated protein kinase kinase 4; SERK1; dual specificity mitogen-activated protein kinase kinase 4; JNKK1; MEK4; MKK4; PRKMK4; MEK 4; MAPKK 4; SAPK kinase 1; MAPK/ERK kinase 4; SAPK/ERK kinase 1; MAP kinase kinase 4; JNK-activated kinase 1; JNK activating kinase 1; JNK-activating kinase 1; c-Jun N-terminal kinase kinase 1; stress-activated protein kinase kinase 1; JNKK; SEK1; MAPKK4; SAPKK1; SAPKK-1	Human	P. pastoris

HY-P700592

MAP2K6 Protein, Human (Baculovirus, His) MAP2K6; mitogen-activated protein kinase kinase 6; MEK6; MKK6; MAPKK6; PRKMK6; SAPKK3; protein kinase, mitogen-activated, kinase 6 (MAP kinase kinase 6); EC 2.7.12.2; Dual specificity mitogen-activated protein kinase kinase 6; MAP kinase kinase 6; MAPK/ERK kinase 6	Human	Sf9 insect cells

Cat. No.	Product Name

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.

HY-B1456AS

Fenoprofen-13C6(sodium salt hydrate)

Fenoprofen-¹³C₆ (sodium hydrate) is the ¹³C labeled Fenoprofen (HY-B1456A). Fenoprofen is a nonsteroidal anti-inflammatory agent (NSAID). Fenoprofen can be used to to relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. Fenoprofen is an allosteric enhancer for melanocortin receptors. Fenoprofen also increases ERK1/2 activation[1][2][3].

HY-14188S

Amiodarone-d4 hydrochloride

Amiodarone-d₄ (hydrochloride) is the deuterium labeled Amiodarone hydrochloride. Amiodarone hydrochloride, a benzofuran-based Class III antiarrhythmic agent, inhibits WT outwardIhERG tails with an IC50 of ∼45 nM[1]. Amiodarone hydrochloride induces cell proliferation and myofibroblast differentiation via ERK1/2 and p38 MAPK signaling in fibroblasts[2]. Amiodarone hydrochloride can be used in the research of both supraventricular and ventricular arrhythmias[1].

HY-17600S

Acalabrutinib-d4

Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor[1].

HY-113509S

Lipoxin A4-d5

Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

HY-19696S

Tauroursodeoxycholate-d5
Tauroursodeoxycholate-d₅ is the deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-19700S

trans-Zeatin-d5
trans-Zeatin-d₅ is deuterium labeled trans-Zeatin. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.

HY-19696S1

Tauroursodeoxycholate-d4
Tauroursodeoxycholate-d₄ is deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-19696S2

Tauroursodeoxycholate-d4-1
Tauroursodeoxycholate-d₄-1 is the deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-19696AS

Tauroursodeoxycholate-d4 sodium
Tauroursodeoxycholate-d₄ (sodium) is the deuterium labeled Tauroursodeoxycholate sodium. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-142283AS

Dosimertinib mesylate
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-B0185AS

Lidocaine-d10 hydrochloride

Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-B0185S1

Lidocaine-d10

Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-B0185AS1

Lidocaine-d6 hydrochloride

Lidocaine-d₆ (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

HY-B0185S

Lidocaine-d10 N-Oxide

N-Oxide Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-142283

Dosimertinib
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80122

ERK5 Rabbit mAb
WB, ICC/IF, IP, FC Human, Mouse

Rabbit Monoclonal Antibody to ERK5
HY-P80391

ERK1 Rabbit mAb
WB, ICC/IF, IHC-P, IP, FC Human, Mouse

Rabbit Monoclonal Antibody to ERK1
HY-P80394

ERK2 Rabbit mAb
WB, ICC/IF, IHC-P, IP, FC Human, Mouse, Rat

Rabbit Monoclonal Antibody to ERK2
HY-P80393

ERK1/2 Rabbit mAb
WB, ICC/IF, IP, FC Human, Mouse, Rat

Rabbit Monoclonal Antibody to ERK1/2
HY-P80392

Erk1 (pT202/pY204) + Erk2 (pT185/pY187) Rabbit mAb
WB, IP, IHC-P Human

Rabbit Monoclonal Antibody to Erk1 (pT202/pY204) + Erk2 (pT185/pY187)

HY-P80832

Phospho-MEK1 (Ser298) Rabbit mAb MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF	Human, Mouse, Rat
Phospho-MEK1 (Ser298) Rabbit mAb is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to Phospho-MEK1 (Ser298). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80833

Phospho-MEK1 (Thr292) Rabbit mAb MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB	Mouse, Rat
Rabbit Monoclonal Antibody to MEK1 (phospho T292)

HY-P80813

Phospho-ERK1/2 (Thr202/Thr185) Rabbit mAb
MAPK1/MAPK3
WB, IP Human, Hamster, Rat

Rabbit Monoclonal Antibody to ERK1/2 (Phospho Thr202/Thr185)
HY-P80815

Phospho-ERK1/2 (Tyr204/Tyr187) Rabbit pAb
MAPK1/MAPK3
WB, IHC-P, ICC/IF Human, Mouse, Rat

Rabbit Polyclonal Antibody to ERK1/2 (phospho Tyr204/Tyr187)
HY-P80814

Phospho-ERK1/2 (Thr202/Tyr204)/(Thr185/Tyr187) Rabbit pAb
MAPK1/MAPK3
WB Human, Mouse, Rat

Rabbit Polyclonal Antibody to ERK1/2 (phospho Thr202/Tyr204)/(phospho Thr185/Tyr187)

HY-P80834

Phospho-MEK4 (Ser80) Rabbit mAb MAP2K4; JNKK1; MEK4; MKK4; PRKMK4; SEK1; SERK1; SKK1; Dual specificity mitogen-activated protein kinase kinase 4; MAP kinase kinase 4; MAPKK 4; JNK-activating kinase 1; MAPK/ERK kinase 4; MEK 4; SAPK/ERK kinase 1; SEK1; Stress-activated pro	WB, IP	Human
Rabbit Monoclonal Antibody to MEK4/MKK4 (phospho S80)

HY-P80549

ASK1 Rabbit pAb MAP3K5; ASK1; MAPKKK5; MEKK5; Mitogen-activated protein kinase kinase kinase 5; Apoptosis signal-regulating kinase 1; ASK-1; MAPK/ERK kinase kinase 5; MEK kinase 5; MEKK 5	WB, IHC-P, ICC/IF, FC	Human, Mouse
Rabbit Polyclonal Antibody to ASK1

HY-P80792

Phospho-ASK1 (Ser966) Rabbit pAb MAP3K5; ASK1; MAPKKK5; MEKK5; Mitogen-activated protein kinase kinase kinase 5; Apoptosis signal-regulating kinase 1; ASK-1; MAPK/ERK kinase kinase 5; MEK kinase 5; MEKK 5	WB, IHC-P	Human, Mouse, Rat
Rabbit Polyclonal Antibody to ASK1 (phospho S966)

ERK

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products